[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Acumedia Manufacturers, Inc.\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":98},{"warningLetters":4,"total":97},[5,32,55,76],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":27,"body_fetched_at":28,"delivery_method":29,"recipient_title":19,"reference_number":30,"action_taken_date":31,"medical_device_id":19,"response_letter_date":19},332,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2026-02-17T05:00:00Z\">02\u002F17\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-02-06T05:00:00Z\">02\u002F06\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcosmetic-manufacturers-pty-ltd-719225-02062026\">Cosmetic Manufacturers Pty Ltd.\u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA EMAIL WITH READ RECEIPT\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-26-43\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Valentine P. Fittler\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO &amp; Managing Director \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Cosmetic Manufacturers Pty Ltd.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>PO Box 5767\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Queensland Mail Centre\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Bundall\u003C\u002Fspan> \u003Cspan>QLD\u003C\u002Fspan> \u003Cspan>9726\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Australia\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-26-43\u003C\u002Fp>\u003Cp>February 6, 2026\u003C\u002Fp>\u003Cp>Dear Mr. Fittler:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Cosmetic Manufacturers (Aust) Pty Ltd., FEI 3007187387, at 14 Kingston Drive, Helensvale, Queensland, from March 31 to April 8, 2025.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>We reviewed your April 23, 2025, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\u003Cp>During our inspection, our investigator observed specific violations including, but not limited to, the following.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release (21 CFR 211.165(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You did not ensure drug products manufactured at your facility were evaluated for all critical quality attributes. You did not test \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug products for identity and strength of the active ingredient \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and particulate and foreign matter. Additionally, you did not evaluate the preservative content of \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug product.\u003C\u002Fp>\u003Cp>Your response is inadequate. We acknowledge your commitment to validate an analytical test method for \u003Cstrong>(b)(4)\u003C\u002Fstrong> assay and to implement \u003Cstrong>(b)(4)\u003C\u002Fstrong> assay testing for future batch release and retrospective testing of reserve samples of \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug products. However, you do not commit to reevaluate your batch release criteria to identify all critical quality attributes and establish appropriate batch release criteria.\u003C\u002Fp>\u003Cp>In response to this letter provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\u003C\u002Fli>\u003Cli>An updated list of chemical and microbial specifications, including test methods, used to analyze each batch of your drug products before a batch disposition decision. Include:\u003Cbr>o A detailed description of how you will ensure drug products manufactured for distribution to the United States are held to suitable batch release criteria. Include any references to sources of information (e.g., specific qualified consultants and published materials including the United States Pharmacopeia).\u003Cbr>o Scientific justification for each chemical and microbial specification.\u003C\u002Fli>\u003Cli>An action plan and timelines for conducting full chemical and microbiological testing of reserve samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter.\u003C\u002Fli>\u003Cli>A summary of all results obtained from testing reserve samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity (21 CFR 211.160(b)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong> is used in the formulation of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> products and cleaning of production equipment. Your testing and specifications of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> are inadequate. You did not test samples of \u003Cstrong>(b)(4)\u003C\u002Fstrong> for all significant quality attributes, including \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You also have not established suitability of test methods, including evaluating whether your drug product formulations intrinsically inhibit microbiological growth during bioburden testing.\u003C\u002Fp>\u003Cp>Your response is inadequate. We acknowledge your commitment to implement \u003Cstrong>(b)(4)\u003C\u002Fstrong> testing of \u003Cstrong>(b)(4)\u003C\u002Fstrong> samples. However, in your response to this violation and several others you noted that the basis of your procedures is to comply with local regulatory requirement(s) despite manufacturing drug products intended for distribution to the United States. It is incumbent upon your firm to ensure it complies with all applicable U.S. statutory and regulatory requirements prior to distributing drug products to the U.S. market.\u003C\u002Fp>\u003Cp>You also commit to revalidate your \u003Cstrong>(b)(4)\u003C\u002Fstrong> system over a period of \u003Cstrong>(b)(4)\u003C\u002Fstrong> and determine whether you need to adjust your routine sampling schedule based on the results. You currently test the \u003Cstrong>(b)(4)\u003C\u002Fstrong> loop \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You do not provide scientific justification for limiting the validation of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> system to a \u003Cstrong>(b)(4)\u003C\u002Fstrong> period or for your sampling schedules for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> loop \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>We acknowledge your commitment to conduct “bioburden suitability studies” on bulk samples to assess any potential growth inhibition of the drug products. However, you do not explain how these studies will be performed, nor do you commit to provide this information to FDA in a future response.\u003C\u002Fp>\u003Cp>Appropriate bioburden controls must be implemented to provide assurance that your subsequent terminal sterilization processes will be successful.\u003C\u002Fp>\u003Cp>In response to this letter provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive assessment of all component and product specifications and limits associated with the manufacture of drugs for the U.S. market to identify and correct those that do not align with U.S. requirements.\u003C\u002Fli>\u003Cli>A procedure for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> system monitoring that specifies routine microbial testing of \u003Cstrong>(b)(4)\u003C\u002Fstrong> to ensure its acceptability for use in each batch of drug products produced by your firm.\u003C\u002Fli>\u003Cli>The current action\u002Falert limits for total counts and objectionable organisms used for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> system.\u003C\u002Fli>\u003Cli>A procedure governing your program for ongoing control and monitoring that ensures the system consistently produces \u003Cstrong>(b)(4)\u003C\u002Fstrong> that meets \u003Cstrong>(b)(4)\u003C\u002Fstrong>, USP monograph specifications and appropriate microbial limits.\u003C\u002Fli>\u003Cli>The protocol, sampling method(s), and test method(s) used to assess potential growth inhibition of drug products you manufacture for distribution to the United States.\u003C\u002Fli>\u003Cli>The protocol and executed protocol report supporting the detectability of \u003Cem>Burkholderia cepacia\u003C\u002Fem> using your existing test method for detection of Pseudomonads.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>3. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your manufacturing process validation was inadequate for \u003Cstrong>(b)(4)\u003C\u002Fstrong> bulk solutions. Your sampling methodologies lacked scientific justification, and you did not you test for the concentration of active ingredient \u003Cstrong>(b)(4)\u003C\u002Fstrong> in each product. Your manufacturing process validation for \u003Cstrong>(b)(4)\u003C\u002Fstrong> bulk solution relied on samples taken from the \u003Cstrong>(b)(4)\u003C\u002Fstrong> of a \u003Cstrong>(b)(4)\u003C\u002Fstrong> vessel that were analyzed for \u003Cstrong>(b)(4)\u003C\u002Fstrong> content. Your manufacturing process validation for \u003Cstrong>(b)(4)\u003C\u002Fstrong> bulk solution relied on samples taken from the \u003Cstrong>(b)(4)\u003C\u002Fstrong> of a \u003Cstrong>(b)(4)\u003C\u002Fstrong> vessel that were analyzed for appearance and \u003Cstrong>(b)(4)\u003C\u002Fstrong> content. The \u003Cstrong>(b)(4)\u003C\u002Fstrong> bulk solutions are \u003Cstrong>(b)(4)\u003C\u002Fstrong> and may be challenging to achieve uniform distribution of the ingredients due to their composition of approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong>% \u003Cstrong>(b)(4)\u003C\u002Fstrong>, respectively.\u003C\u002Fp>\u003Cp>Our review of the 2023 manufacturing process validation report for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> bulk solution also revealed it failed to meet the pre-established \u003Cstrong>(b)(4)\u003C\u002Fstrong> content percent coefficient of variation criterion of \u003Cstrong>(b)(4)\u003C\u002Fstrong>% with a calculated value of \u003Cstrong>(b)(4)\u003C\u002Fstrong>%. The validation report states, “For the purposes of this validation exercise, this result will be accepted, and no further action is required.”\u003C\u002Fp>\u003Cp>Our review of documents collected during the inspection also revealed you do not ensure \u003Cstrong>(b)(4)\u003C\u002Fstrong> drugs are manufactured in areas with adequate environmental controls. For example, your procedure governing environmental monitoring identifies your action level for passive air monitoring as \u003Cstrong>(b)(4)\u003C\u002Fstrong> colony forming units\u002Fplate following a \u003Cstrong>(b)(4)\u003C\u002Fstrong> exposure in manufacturing areas. If the product exposure poses substantial hazard (e.g., filling operation in which containers are \u003Cstrong>(b)(4)\u003C\u002Fstrong> or are exposed for more than a \u003Cstrong>(b)(4)\u003C\u002Fstrong> before closing), then the product should be filled in grade A with at least a grade C background. Otherwise, grade B or C air classifications may be appropriate for filling prior to terminal sterilization. Appropriate microbial levels should be established for these zones. In addition, the filling and closing operation should be adequately separated from the surrounding room environment, and it should be conducted under extensive HEPA filter coverage.\u003C\u002Fp>\u003Cp>Your response is inadequate. You commit to draft and execute a revised \u003Cstrong>(b)(4)\u003C\u002Fstrong> validation protocol for each of the drug products you manufacture for the U.S. market. You do not include justification for the methodology of sampling from the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” versus other sampling methods that provide a more scientifically sound approach. You commit to hire a third-party expert to train the head of your quality organization on validation principles. However, you do not commit to provide documentation supporting how this training will equip your quality organization with the knowledge necessary to ensure validation activities are aligned with U.S. regulatory requirements.\u003C\u002Fp>\u003Cp>In response to this letter provide:\u003C\u002Fp>\u003Cul>\u003Cli>A detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process performance qualification, and ongoing monitoring of both intra-batch and inter-batch variation, including active ingredient concentration, to ensure a continuing state of control.\u003C\u002Fli>\u003Cli>A timeline for performing appropriate process performance qualification for each of your marketed drug products. Also provide a risk assessment and any follow up actions to be taken for the distributed drug products produced without prior performance of any process validation studies.\u003C\u002Fli>\u003Cli>Process performance protocol(s) and written procedures for qualification of equipment and facilities. If not explicitly stated in the process performance protocols, include an explanation for each process control parameter and acceptance criterion.\u003C\u002Fli>\u003Cli>A detailed program for designing, validating, maintaining, controlling, and monitoring each of your manufacturing processes that includes vigilant monitoring of intra-batch and inter-batch variation to ensure an ongoing state of control. Also, include your program for qualification of your equipment and facility.\u003C\u002Fli>\u003Cli>An independent assessment of your environmental monitoring program including, but not limited to, establishing appropriate limits, sampling locations and frequencies, investigating deviations, and trend analysis, and a comprehensive CAPA plan.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>4. Your firm failed to use equipment in the manufacture, processing, packing, or holding of drug products that is of appropriate design, adequate size, and suitably located to facilitate operations for its intended use and for its cleaning and maintenance (21 CFR 211.63).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You have not demonstrated all equipment used to manufacture finished drug products is suitable for its intended use. You qualified the \u003Cstrong>(b)(4)\u003C\u002Fstrong> filler machine for the filling of \u003Cstrong>(b)(4)\u003C\u002Fstrong> in \u003Cstrong>(b)(4)\u003C\u002Fstrong> mL bottles following an inadequate product \u003Cstrong>(b)(4)\u003C\u002Fstrong> approach. For example, you filled \u003Cstrong>(b)(4)\u003C\u002Fstrong> mL of a \u003Cstrong>(b)(4)\u003C\u002Fstrong> product into \u003Cstrong>(b)(4)\u003C\u002Fstrong> bottles and \u003Cstrong>(b)(4)\u003C\u002Fstrong> mL of a \u003Cstrong>(b)(4)\u003C\u002Fstrong> product into \u003Cstrong>(b)(4)\u003C\u002Fstrong> bottles. The qualification documentation does not provide adequate scientific justification for this limited \u003Cstrong>(b)(4)\u003C\u002Fstrong> approach. It also does not explain how \u003Cstrong>(b)(4)\u003C\u002Fstrong> batch size products like \u003Cstrong>(b)(4)\u003C\u002Fstrong>, which has a theoretical batch size of \u003Cstrong>(b)(4)\u003C\u002Fstrong> bottles, fits within the \u003Cstrong>(b)(4)\u003C\u002Fstrong> approach. The \u003Cstrong>(b)(4)\u003C\u002Fstrong> filler machine also failed to meet the qualification criterion for fill weight percent coefficient of variation for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> product filled in \u003Cstrong>(b)(4)\u003C\u002Fstrong> mL bottles.\u003C\u002Fp>\u003Cp>You have also not established whether your cleaning procedures consistently reduce chemical and microbiological residues to acceptable levels. The cleaning validation protocol was not designed to demonstrate reproducibility of the cleaning process. For example, the cleaning validation protocol required \u003Cstrong>(b)(4)\u003C\u002Fstrong> swab samples to be taken from different locations for each of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> qualification runs. Your cleaning validation also did not adequately justify the decision to use a \u003Cstrong>(b)(4)\u003C\u002Fstrong> tank in lieu of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> tank used to manufacture the \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug products. For example, there is no discussion of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> tanks’ material(s) of construction and interior features (e.g., drains, ports, \u003Cstrong>(b)(4)\u003C\u002Fstrong>).\u003C\u002Fp>\u003Cp>Your response is inadequate. You commit to requalify your \u003Cstrong>(b)(4)\u003C\u002Fstrong> filler machine using a “maximum batch size [of] \u003Cstrong>(b)(4)\u003C\u002Fstrong>” by approximately October 2026 but do not commit to reassess your protocol design (e.g., \u003Cstrong>(b)(4)\u003C\u002Fstrong> approach) and acceptance criteria. Additionally, you do not commit to implement interim actions to ensure drug products manufactured on the machine meet their required quality attributes. You also commit to revise your written procedure for cleaning validation activities to verify the cleaning process will consistently render surfaces suitably clean. However, you do not commit to adequately justify your various \u003Cstrong>(b)(4)\u003C\u002Fstrong> methodologies and to revalidate your cleaning process.\u003C\u002Fp>\u003Cp>In response to this letter provide:\u003C\u002Fp>\u003Cul>\u003Cli>Your plan for ensuring that each piece of equipment used to manufacture drug products is appropriately qualified for its purpose. Include a detailed explanation for each use of \u003Cstrong>(b)(4)\u003C\u002Fstrong> in lieu of evaluating different elements separately.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Appropriate improvements to your cleaning validation program with special emphasis on incorporating conditions identified as worst case in your drug manufacturing operation. This should include but not be limited to identification and evaluation of all worst-case:\u003Cbr>o drugs with higher toxicities\u003Cbr>o drugs with higher drug potencies\u003Cbr>o drugs of lower solubility in their cleaning solvents\u003Cbr>o drugs with characteristics that make their residues difficult to clean\u003Cbr>o swabbing locations for areas that are most difficult to clean\u003Cbr>o maximum hold times before cleaning\u003C\u002Fp>\u003Cul>\u003Cli>In addition, describe the steps that must be taken in your change management system before introduction of new manufacturing equipment or a new product. A summary of updated SOPs that ensure an appropriate program is in place for verification and validation of cleaning procedures for products, processes, and equipment.\u003C\u002Fli>\u003Cli>The date by which your cleaning processes for drug manufacturing equipment will be validated.\u003C\u002Fli>\u003Cli>Interim controls to ensure equipment used to manufacture drug products is suitably clean.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Responsibilities as a Contractor\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Drugs must be manufactured in conformance with CGMP. FDA is aware that many drug manufacturers use independent contractors such as production facilities, testing laboratories, packagers, and labelers. FDA regards contractors as extensions of the manufacturer.\u003C\u002Fp>\u003Cp>You and your customer, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, have a quality agreement regarding the manufacture of drug products. You are responsible for the quality of drugs you produce as a contract facility regardless of agreements in place with product owners. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&amp;C Act for safety, identity, strength, quality, and purity. See FDA’s guidance document Contract Manufacturing Arrangements for Drugs: Quality Agreements at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fcontract-manufacturing-arrangements-drugs-quality-agreements-guidance-industry.\u003C\u002Fp>\u003Cp>Please note that FDA issued a Warning Letter to \u003Cstrong>(b)(4)\u003C\u002Fstrong> on \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Additionally, the drug products \u003Cstrong>(b)(4)\u003C\u002Fstrong> were placed on Import Alert 66-41 on \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>\u003Cstrong>Drug Production Ceased\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>We acknowledge your commitment to cease production of all drugs at this facility for the U.S. market.\u003C\u002Fp>\u003Cp>If you plan to resume any manufacturing operations regulated under the FD&amp;C Act, notify this office before resuming your drug manufacturing operations. You are responsible for resolving all deficiencies and systemic flaws to ensure your firm is capable of ongoing CGMP compliance. In your notification to the Agency, provide a summary of your remediations to demonstrate that you have appropriately completed all corrective action and preventive action (CAPA).\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>FDA placed all drugs and drug products offered for import into the United States from your firm on Import Alert 66-40 on January 8, 2026.\u003C\u002Fp>\u003Cp>Correct any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\u003Cp>Failure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at Cosmetic Manufacturers (Aust) Pty Ltd.,14 Kingston Drive, Helensvale, into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3007187387 and ATTN: Jason F. Chancey.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA EMAIL WITH READ RECEIPT\n\nReference #:\n\n320-26-43\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Valentine P. Fittler\n\nRecipient Title\n\nCEO & Managing Director\n\nCosmetic Manufacturers Pty Ltd.\n\nPO Box 5767\n\nQueensland Mail Centre\n\nBundall QLD 9726\n\nAustralia\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-26-43\nFebruary 6, 2026\nDear Mr. Fittler:\nThe United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Cosmetic Manufacturers (Aust) Pty Ltd., FEI 3007187387, at 14 Kingston Drive, Helensvale, Queensland, from March 31 to April 8, 2025.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nWe reviewed your April 23, 2025, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\nDuring our inspection, our investigator observed specific violations including, but not limited to, the following.\n1. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release (21 CFR 211.165(a)).\nYou did not ensure drug products manufactured at your facility were evaluated for all critical quality attributes. You did not test (b)(4) drug products for identity and strength of the active ingredient (b)(4), and particulate and foreign matter. Additionally, you did not evaluate the preservative content of (b)(4) drug product.\nYour response is inadequate. We acknowledge your commitment to validate an analytical test method for (b)(4) assay and to implement (b)(4) assay testing for future batch release and retrospective testing of reserve samples of (b)(4) drug products. However, you do not commit to reevaluate your batch release criteria to identify all critical quality attributes and establish appropriate batch release criteria.\nIn response to this letter provide:\nA comprehensive assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\nAn updated list of chemical and microbial specifications, including test methods, used to analyze each batch of your drug products before a batch disposition decision. Include:\no A detailed description of how you will ensure drug products manufactured for distribution to the United States are held to suitable batch release criteria. Include any references to sources of information (e.g., specific qualified consultants and published materials including the United States Pharmacopeia).\no Scientific justification for each chemical and microbial specification.\nAn action plan and timelines for conducting full chemical and microbiological testing of reserve samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter.\nA summary of all results obtained from testing reserve samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\n2. Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity (21 CFR 211.160(b)).\n(b)(4) is used in the formulation of your (b)(4) products and cleaning of production equipment. Your testing and specifications of your (b)(4) are inadequate. You did not test samples of (b)(4) for all significant quality attributes, including (b)(4). You also have not established suitability of test methods, including evaluating whether your drug product formulations intrinsically inhibit microbiological growth during bioburden testing.\nYour response is inadequate. We acknowledge your commitment to implement (b)(4) testing of (b)(4) samples. However, in your response to this violation and several others you noted that the basis of your procedures is to comply with local regulatory requirement(s) despite manufacturing drug products intended for distribution to the United States. It is incumbent upon your firm to ensure it complies with all applicable U.S. statutory and regulatory requirements prior to distributing drug products to the U.S. market.\nYou also commit to revalidate your (b)(4) system over a period of (b)(4) and determine whether you need to adjust your routine sampling schedule based on the results. You currently test the (b)(4) loop (b)(4). You do not provide scientific justification for limiting the validation of your (b)(4) system to a (b)(4) period or for your sampling schedules for the (b)(4) loop (b)(4).\nWe acknowledge your commitment to conduct “bioburden suitability studies” on bulk samples to assess any potential growth inhibition of the drug products. However, you do not explain how these studies will be performed, nor do you commit to provide this information to FDA in a future response.\nAppropriate bioburden controls must be implemented to provide assurance that your subsequent terminal sterilization processes will be successful.\nIn response to this letter provide:\nA comprehensive assessment of all component and product specifications and limits associated with the manufacture of drugs for the U.S. market to identify and correct those that do not align with U.S. requirements.\nA procedure for your (b)(4) system monitoring that specifies routine microbial testing of (b)(4) to ensure its acceptability for use in each batch of drug products produced by your firm.\nThe current action\u002Falert limits for total counts and objectionable organisms used for your (b)(4) system.\nA procedure governing your program for ongoing control and monitoring that ensures the system consistently produces (b)(4) that meets (b)(4), USP monograph specifications and appropriate microbial limits.\nThe protocol, sampling method(s), and test method(s) used to assess potential growth inhibition of drug products you manufacture for distribution to the United States.\nThe protocol and executed protocol report supporting the detectability of Burkholderia cepacia using your existing test method for detection of Pseudomonads.\n3. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\nYour manufacturing process validation was inadequate for (b)(4) bulk solutions. Your sampling methodologies lacked scientific justification, and you did not you test for the concentration of active ingredient (b)(4) in each product. Your manufacturing process validation for (b)(4) bulk solution relied on samples taken from the (b)(4) of a (b)(4) vessel that were analyzed for (b)(4) content. Your manufacturing process validation for (b)(4) bulk solution relied on samples taken from the (b)(4) of a (b)(4) vessel that were analyzed for appearance and (b)(4) content. The (b)(4) bulk solutions are (b)(4) and may be challenging to achieve uniform distribution of the ingredients due to their composition of approximately (b)(4)% (b)(4), respectively.\nOur review of the 2023 manufacturing process validation report for the (b)(4) bulk solution also revealed it failed to meet the pre-established (b)(4) content percent coefficient of variation criterion of (b)(4)% with a calculated value of (b)(4)%. The validation report states, “For the purposes of this validation exercise, this result will be accepted, and no further action is required.”\nOur review of documents collected during the inspection also revealed you do not ensure (b)(4) drugs are manufactured in areas with adequate environmental controls. For example, your procedure governing environmental monitoring identifies your action level for passive air monitoring as (b)(4) colony forming units\u002Fplate following a (b)(4) exposure in manufacturing areas. If the product exposure poses substantial hazard (e.g., filling operation in which containers are (b)(4) or are exposed for more than a (b)(4) before closing), then the product should be filled in grade A with at least a grade C background. Otherwise, grade B or C air classifications may be appropriate for filling prior to terminal sterilization. Appropriate microbial levels should be established for these zones. In addition, the filling and closing operation should be adequately separated from the surrounding room environment, and it should be conducted under extensive HEPA filter coverage.\nYour response is inadequate. You commit to draft and execute a revised (b)(4) validation protocol for each of the drug products you manufacture for the U.S. market. You do not include justification for the methodology of sampling from the “(b)(4)” versus other sampling methods that provide a more scientifically sound approach. You commit to hire a third-party expert to train the head of your quality organization on validation principles. However, you do not commit to provide documentation supporting how this training will equip your quality organization with the knowledge necessary to ensure validation activities are aligned with U.S. regulatory requirements.\nIn response to this letter provide:\nA detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process performance qualification, and ongoing monitoring of both intra-batch and inter-batch variation, including active ingredient concentration, to ensure a continuing state of control.\nA timeline for performing appropriate process performance qualification for each of your marketed drug products. Also provide a risk assessment and any follow up actions to be taken for the distributed drug products produced without prior performance of any process validation studies.\nProcess performance protocol(s) and written procedures for qualification of equipment and facilities. If not explicitly stated in the process performance protocols, include an explanation for each process control parameter and acceptance criterion.\nA detailed program for designing, validating, maintaining, controlling, and monitoring each of your manufacturing processes that includes vigilant monitoring of intra-batch and inter-batch variation to ensure an ongoing state of control. Also, include your program for qualification of your equipment and facility.\nAn independent assessment of your environmental monitoring program including, but not limited to, establishing appropriate limits, sampling locations and frequencies, investigating deviations, and trend analysis, and a comprehensive CAPA plan.\n4. Your firm failed to use equipment in the manufacture, processing, packing, or holding of drug products that is of appropriate design, adequate size, and suitably located to facilitate operations for its intended use and for its cleaning and maintenance (21 CFR 211.63).\nYou have not demonstrated all equipment used to manufacture finished drug products is suitable for its intended use. You qualified the (b)(4) filler machine for the filling of (b)(4) in (b)(4) mL bottles following an inadequate product (b)(4) approach. For example, you filled (b)(4) mL of a (b)(4) product into (b)(4) bottles and (b)(4) mL of a (b)(4) product into (b)(4) bottles. The qualification documentation does not provide adequate scientific justification for this limited (b)(4) approach. It also does not explain how (b)(4) batch size products like (b)(4), which has a theoretical batch size of (b)(4) bottles, fits within the (b)(4) approach. The (b)(4) filler machine also failed to meet the qualification criterion for fill weight percent coefficient of variation for the (b)(4) product filled in (b)(4) mL bottles.\nYou have also not established whether your cleaning procedures consistently reduce chemical and microbiological residues to acceptable levels. The cleaning validation protocol was not designed to demonstrate reproducibility of the cleaning process. For example, the cleaning validation protocol required (b)(4) swab samples to be taken from different locations for each of the (b)(4) qualification runs. Your cleaning validation also did not adequately justify the decision to use a (b)(4) tank in lieu of the (b)(4) tank used to manufacture the (b)(4) drug products. For example, there is no discussion of the (b)(4) tanks’ material(s) of construction and interior features (e.g., drains, ports, (b)(4)).\nYour response is inadequate. You commit to requalify your (b)(4) filler machine using a “maximum batch size [of] (b)(4)” by approximately October 2026 but do not commit to reassess your protocol design (e.g., (b)(4) approach) and acceptance criteria. Additionally, you do not commit to implement interim actions to ensure drug products manufactured on the machine meet their required quality attributes. You also commit to revise your written procedure for cleaning validation activities to verify the cleaning process will consistently render surfaces suitably clean. However, you do not commit to adequately justify your various (b)(4) methodologies and to revalidate your cleaning process.\nIn response to this letter provide:\nYour plan for ensuring that each piece of equipment used to manufacture drug products is appropriately qualified for its purpose. Include a detailed explanation for each use of (b)(4) in lieu of evaluating different elements separately.\nAppropriate improvements to your cleaning validation program with special emphasis on incorporating conditions identified as worst case in your drug manufacturing operation. This should include but not be limited to identification and evaluation of all worst-case:\no drugs with higher toxicities\no drugs with higher drug potencies\no drugs of lower solubility in their cleaning solvents\no drugs with characteristics that make their residues difficult to clean\no swabbing locations for areas that are most difficult to clean\no maximum hold times before cleaning\nIn addition, describe the steps that must be taken in your change management system before introduction of new manufacturing equipment or a new product. A summary of updated SOPs that ensure an appropriate program is in place for verification and validation of cleaning procedures for products, processes, and equipment.\nThe date by which your cleaning processes for drug manufacturing equipment will be validated.\nInterim controls to ensure equipment used to manufacture drug products is suitably clean.\nResponsibilities as a Contractor\nDrugs must be manufactured in conformance with CGMP. FDA is aware that many drug manufacturers use independent contractors such as production facilities, testing laboratories, packagers, and labelers. FDA regards contractors as extensions of the manufacturer.\nYou and your customer, (b)(4), have a quality agreement regarding the manufacture of drug products. You are responsible for the quality of drugs you produce as a contract facility regardless of agreements in place with product owners. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&C Act for safety, identity, strength, quality, and purity. See FDA’s guidance document Contract Manufacturing Arrangements for Drugs: Quality Agreements at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fcontract-manufacturing-arrangements-drugs-quality-agreements-guidance-industry.\nPlease note that FDA issued a Warning Letter to (b)(4) on (b)(4). Additionally, the drug products (b)(4) were placed on Import Alert 66-41 on (b)(4).\nDrug Production Ceased\nWe acknowledge your commitment to cease production of all drugs at this facility for the U.S. market.\nIf you plan to resume any manufacturing operations regulated under the FD&C Act, notify this office before resuming your drug manufacturing operations. You are responsible for resolving all deficiencies and systemic flaws to ensure your firm is capable of ongoing CGMP compliance. In your notification to the Agency, provide a summary of your remediations to demonstrate that you have appropriately completed all corrective action and preventive action (CAPA).\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nFDA placed all drugs and drug products offered for import into the United States from your firm on Import Alert 66-40 on January 8, 2026.\nCorrect any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\nFailure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at Cosmetic Manufacturers (Aust) Pty Ltd.,14 Kingston Drive, Helensvale, into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3007187387 and ATTN: Jason F. Chancey.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research","Cosmetic Manufacturers Pty Ltd.","cosmetic-manufacturers-pty-ltd-719225-02062026","2026-08-18T06:42:28.498414+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcosmetic-manufacturers-pty-ltd-719225-02062026","2026-10-26T08:08:18.422345+00:00","Warning Letter","Issued","2026-02-17","719225","Drugs","Mr. Valentine P. Fittler","2026-08-19T04:57:44.11+00:00","VIA EMAIL WITH READ RECEIPT","320-26-43","2026-02-06",{"id":33,"raw":34,"subject":40,"body_html":41,"body_text":42,"firm_name":43,"letter_id":44,"created_at":45,"fei_number":19,"letter_url":46,"updated_at":47,"action_type":22,"case_status":23,"posted_date":48,"marcs_cms_no":49,"product_type":50,"closeout_date":19,"issuing_office":38,"recipient_name":51,"body_fetched_at":52,"delivery_method":53,"recipient_title":19,"reference_number":19,"action_taken_date":54,"medical_device_id":19,"response_letter_date":19},22009,[35,36,37,38,39,13,13,13],"\u003Ctime datetime=\"2026-10-27T04:00:00Z\">10\u002F27\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-09-22T04:00:00Z\">09\u002F22\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Frama-food-manufacture-corp-730689-09222026\">Rama Food Manufacture Corp. \u003C\u002Fa>","Human Foods Program","CGMP\u002FFood\u002FPrepared, Packed or Held Under Insanitary Conditions\u002FAdulterated\u002FL. monocytogenes\u003Cbr \u002F>\r\n","CGMP\u002FFood\u002FPrepared, Packed or Held Under Insanitary Conditions\u002FAdulterated\u002FL. monocytogenes","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA ELECTRONIC DELIVERY\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Ms. Karen Ving, President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Jonathan Ving, General Manager \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Rama Food Manufacture Corp. \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1486 E Cedar Street\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Ontario\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>91761-8300\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:Jonathan.Ving@ramafood.com\"> Jonathan.Ving@ramafood.com \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Human Foods Program\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>September 22, 2026\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>WARNING LETTER\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Re: CMS #730689\u003C\u002Fp>\u003Cp>Dear Ms. Ving and Mr. Ving:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected two of your Rama Food Manufacture Corp. food manufacturing facilities located at 1486 E Cedar Street, Ontario, California 91761 and 2131 S Parco Avenue, Ontario, California 91761 from January 27 through February 26, 2026. Both facilities manufacture ready-to-eat (RTE) rice noodles (various noodle sizes\u002Ftypes).\u003C\u002Fp>\u003Cp>During our inspections, FDA investigators observed serious violations of the Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Human Food regulation (CGMP &amp; PC rule), Title 21, Code of Federal Regulations, Part 117 (21 CFR Part 117). Additionally, FDA collected environmental samples (i.e., swabs) from various areas in both facilities. FDA laboratory analysis of the environmental swabs found the presence of \u003Cem>Listeria innocua\u003C\u002Fem> and \u003Cem>grayi\u003C\u002Fem> in your S Parco Avenue facility and \u003Cem>L. grayi\u003C\u002Fem> in your E Cedar Street facility, which are non-human pathogenic \u003Cem>Listeria spp\u003C\u002Fem>. FDA also collected four finished product samples and analyzed them for water activity and pH.\u003C\u002Fp>\u003Cp>Based on FDA’s inspectional findings and analytical results for finished product samples of Pad Thai Rice Stick Noodle, Fresh Rice Stick Noodle Banh Pho Tuoi, and Rice Stick Noodle Big Cut Noodle, we have determined that the RTE rice noodle products manufactured in both of your facilities are adulterated within the meaning of section 402(a)(4) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 342(a)(4)] because they were prepared, packed, or held under insanitary conditions whereby they may have become contaminated with filth or been rendered injurious to health. In addition, failure of the owner, operator, or agent in charge of a covered facility to comply with the preventive control provisions of the CGMP &amp; PC rule (located in subparts A, C, D, E, F, and G of Part 117) is prohibited by section 301(uu) of the Act [21 U.S.C. § 331(uu)]. You may find the Act and further information about the CGMP &amp; PC rule through links on FDA’s website at http:\u002F\u002Fwww.fda.gov.\u003C\u002Fp>\u003Cp>At the conclusion of both inspections, the FDA investigators issued a Form FDA 483 (FDA-483), Inspectional Observations to each facility. We received your written responses to both FDA-483s on March 17, 2026, describing your planned and implemented corrective actions. Based on our review of the inspectional and analytical findings and your responses, we are issuing this letter to advise you of FDA’s continuing concerns and to provide detailed information describing the findings at each of your facilities. We discuss your responses below.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Hazard Analysis and Risk-Based Preventive Controls (21 CFR Part 117, Subpart C):\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>E Cedar Street Facility\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>1. Your written process preventive control procedures were not appropriate to significantly minimize or prevent hazards requiring preventive controls, as required by 21 CFR 117.135(c)(1). Your facility’s written hazard analysis determined that pathogen hazards such as \u003Cem>Bacillus cereus (B. cereus), Salmonella, Listeria monocytogenes (L. monocytogenes),\u003C\u002Fem> and \u003Cem>Clostridium botulinum (C. botulinum)\u003C\u002Fem> required a preventive control. The “Preventive Controls” section of your food safety plan document indicates that such hazards will be significantly minimized or prevented at the rice \u003Cstrong>(b)(4)\u003C\u002Fstrong> to rice \u003Cstrong>(b)(4)\u003C\u002Fstrong>, rice \u003Cstrong>(b)(4)\u003C\u002Fstrong>, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> processing steps. However, a review of your established control methods\u002Fcritical limits for these process preventive controls determined that they may not control the hazards. Additionally, in some cases, monitoring of these parameters was not implemented and\u002For the parameters were not met. Specifically,\u003C\u002Fp>\u003Cp>a. \u003Cstrong>(b)(4)\u003C\u002Fstrong>: Your “Temperature Control of Rice \u003Cstrong>(b)(4)\u003C\u002Fstrong> Tank” process preventive control covering rice \u003Cstrong>(b)(4)\u003C\u002Fstrong> to rice \u003Cstrong>(b)(4)\u003C\u002Fstrong> in your food safety plan lists a critical limit of “Rice \u003Cstrong>(b)(4)\u003C\u002Fstrong> Temperature ≤ \u003Cstrong>(b)(4)\u003C\u002Fstrong>” to be checked “Every \u003Cstrong>(b)(4)\u003C\u002Fstrong>” which does not provide sufficient control for the hazard of \u003Cem>B. cereus\u003C\u002Fem> identified at these processing steps. If the \u003Cstrong>(b)(4)\u003C\u002Fstrong> rice is exposed to temperatures above 70°F for more than three hours cumulatively, pathogens such as B. cereus can grow and produce toxin. FDA recommends referencing Appendix 3, Table 3-B of our \u003Cu>Draft Guidance for Industry: Hazard Analysis and Risk-Based Preventive Controls for Human Food\u003C\u002Fu>, which explains that for the potential hazardous conditions of growth and toxin formation of B. cereus, the recommended maximum cumulative exposure time for product temperatures above 70°F is three hours.\u003C\u002Fp>\u003Cp>Your response to the FDA-483 dated March 17, 2026, included updated time and temperature critical limits for the process preventive control covering the rice \u003Cstrong>(b)(4)\u003C\u002Fstrong> and rice \u003Cstrong>(b)(4)\u003C\u002Fstrong> steps \u003Cstrong>(b)(4)\u003C\u002Fstrong>. As written, your critical limits of \u003Cstrong>(b)(4)\u003C\u002Fstrong> process ≤ \u003Cstrong>(b)(4)\u003C\u002Fstrong> rice temperature ≤ \u003Cstrong>(b)(4)\u003C\u002Fstrong>, \u003Cstrong>(b)(4)\u003C\u002Fstrong> process ≤ \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> rice temperature ≤ \u003Cstrong>(b)(4)\u003C\u002Fstrong> would still allow the soaked and ground rice to be exposed to temperatures above 70°F for up to 3.5 hours cumulatively, which does not appear to provide adequate control for the hazard of \u003Cem>B. cereus\u003C\u002Fem>. Your response also referenced a proposed challenge study as the basis for these critical limits and stated that the results of the study would be provided upon completion. To date, you have not provided additional information to the Agency regarding this issue.\u003C\u002Fp>\u003Cp>b. \u003Cstrong>(b)(4)\u003C\u002Fstrong>: Your “pH Control of Rice \u003Cstrong>(b)(4)\u003C\u002Fstrong>” process preventive control \u003Cstrong>(b)(4)\u003C\u002Fstrong> in your food safety plan lists a critical limit of “Rice \u003Cstrong>(b)(4)\u003C\u002Fstrong>” which may not provide sufficient control for the hazard of pathogen growth and toxin formation, such as \u003Cem>B. cereus\u003C\u002Fem>, identified at this processing step. Your firm stated that \u003Cstrong>(b)(4)\u003C\u002Fstrong> were also added to control for \u003Cem>B. cereus\u003C\u002Fem>; however, you had no written process preventive control for the addition of \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The rice \u003Cstrong>(b)(4)\u003C\u002Fstrong> is \u003Cstrong>(b)(4)\u003C\u002Fstrong> before being \u003Cstrong>(b)(4)\u003C\u002Fstrong> and packaged, exposing the noodles to elevated temperatures for extended periods of time which may allow for the growth of pathogens and\u002For toxin formation, such as \u003Cem>B. cereus\u003C\u002Fem>.\u003C\u002Fp>\u003Cp>On February 12, 2026, our investigators measured the temperature of in-process RTE rice noodle sheets, Lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>, from Lines \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> at the \u003Cstrong>(b)(4)\u003C\u002Fstrong> step at \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> around 9:20 AM. After \u003Cstrong>(b)(4)\u003C\u002Fstrong>, the rice noodle sheets were \u003Cstrong>(b)(4) \u003C\u002Fstrong>approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong>. A \u003Cstrong>(b)(4)\u003C\u002Fstrong> was placed on the stacked sheets, and a fan was blowing on the rice sheets during the \u003Cstrong>(b)(4)\u003C\u002Fstrong> process. At 10:38 AM, the rice noodle sheet temperature measured at 87°F and 87.5°F. At 3:30 PM, our investigators measured the rice noodle sheet temperatures from each line at 80°F and 81.5°F, respectively. The temperatures of rice noodle sheets were above 70°F for 6 hours and 10 minutes when this process was observed during the inspection.\u003C\u002Fp>\u003Cp>Your response to the FDA-483 indicated the use of pH control and \u003Cstrong>(b)(4)\u003C\u002Fstrong> in the rice \u003Cstrong>(b)(4)\u003C\u002Fstrong> to control for the hazards of \u003Cem>B. cereus\u003C\u002Fem> and \u003Cem>C. perfringens\u003C\u002Fem> at “\u003Cstrong>(b)(4)\u003C\u002Fstrong>.” However, the letter you provided from \u003Cstrong>(b)(4)\u003C\u002Fstrong> noted “A product-specific validation (e.g. \u003Cstrong>(b)(4)\u003C\u002Fstrong>) for \u003Cem>B. cereus\u003C\u002Fem> is recommended to specifically support the Food Safety Plan for its control in the noodle process.” You indicated that you were planning a validation study for product \u003Cstrong>(b)(4)\u003C\u002Fstrong> with your microbiological consultant and that you would submit the results once completed. To date, you have not provided such a validation study to the Agency.\u003C\u002Fp>\u003Cp>Additionally, we note that you have not identified the cooling of the cooked rice noodle sheets \u003Cstrong>(b)(4)\u003C\u002Fstrong> as requiring a process preventive control and have not implemented monitoring procedures to ensure the RTE rice noodle sheets are cooled quickly enough to adequately control bacterial growth and\u002For toxin formation during cooling. FDA recommends in the Food Code cooling from 57ºC (135ºF) to 21ºC (70°F) within 2 hours and then further cooling to 5ºC (41°F) within a total of six hours. The cooling time to reduce temperatures to 21ºC (70°F) is important to ensure products are cooled quickly through the optimum temperatures for growth of bacterial pathogens. Your response to the FDA-483 indicates that you intend the rice \u003Cstrong>(b)(4)\u003C\u002Fstrong> pH check and \u003Cstrong>(b)(4)\u003C\u002Fstrong> to provide adequate control for \u003Cem>B. cereus\u003C\u002Fem> growth and\u002For toxin formation through the noodle cooling and drying process. However, as noted above, you have not provided the results of the planned validation study referenced in your response.\u003C\u002Fp>\u003Cp>c. \u003Cstrong>(b)(4)\u003C\u002Fstrong>: Your “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” process preventive control \u003Cstrong>(b)(4)\u003C\u002Fstrong> in your food safety plan lists temperature checks and pH checks as control mechanisms for pathogen growth [\u003Cem>L. monocytogenes\u003C\u002Fem> and \u003Cem>C. botulinum\u003C\u002Fem> in \u003Cstrong>(b)(4)\u003C\u002Fstrong>. For temperature checks, you list a method of “Check Finished Product temperature (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) ≤ \u003Cstrong>(b)(4)\u003C\u002Fstrong>” with a frequency of “\u003Cstrong>(b)(4)\u003C\u002Fstrong>”. Your finished RTE rice noodles are packaged before \u003Cstrong>(b)(4)\u003C\u002Fstrong> without the product temperature being monitored. Most foodborne bacteria and bacterial spores can survive refrigeration, and some relevant organisms can continue growing at or below 40°F. For pH checks you list a method of “Check Finished Product pH ≤ \u003Cstrong>(b)(4)\u003C\u002Fstrong>” with a frequency of “\u003Cstrong>(b)(4)\u003C\u002Fstrong>”. \u003Cstrong>(b)(4)\u003C\u002Fstrong> ≤ \u003Cstrong>(b)(4)\u003C\u002Fstrong> alone may not be adequate for Listeria control and your products were observed to be exposed to temperatures above 40°F for extended periods of time during finished product storage after packaging, which can allow for the growth of \u003Cem>L. monocytogenes\u003C\u002Fem>.\u003C\u002Fp>\u003Cp>Additionally, FDA’s sampling results for your finished rice noodle products demonstrate that you do not consistently meet your critical limit of a pH \u003Cstrong>(b)(4)\u003C\u002Fstrong> in finished products (refer to Table 1 below). Also, you check the pH of \u003Cstrong>(b)(4)\u003C\u002Fstrong>, which is not representative of the entire lot of approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> of rice noodles.\u003C\u002Fp>\u003Cp>Your firm packages RTE rice noodles (various noodle sizes\u002Ftypes) in 1 lb. reduced oxygen packaging (ROP), in \u003Cstrong>(b)(4)\u003C\u002Fstrong> lb. \u003Cstrong>(b)(4)\u003C\u002Fstrong> film packaging, and in \u003Cstrong>(b)(4)\u003C\u002Fstrong> lb. packaging where \u003Cstrong>(b)(4)\u003C\u002Fstrong> is \u003Cstrong>(b)(4)\u003C\u002Fstrong> from the package and bags are \u003Cstrong>(b)(4)\u003C\u002Fstrong> closed (the latter two may create ROP conditions due to permeability of the packaging material). This creates anaerobic conditions that can allow for \u003Cem>C. botulinum\u003C\u002Fem> growth and toxin formation in the absence of adequate product pH and temperature controls. Your control method of a finished product pH of \u003Cstrong>(b)(4)\u003C\u002Fstrong> may provide adequate control for the hazard of \u003Cem>C. botulinum\u003C\u002Fem> at this processing step if properly implemented. However, FDA collected finished product samples from your E Cedar Street facility for pH and water activity analysis. The analysis found that your process did not consistently yield a finished product pH \u003Cstrong>(b)(4)\u003C\u002Fstrong> in accordance with the critical limit established by your firm. The results are summarized in the table below:\u003C\u002Fp>\u003Cp>\u003Cem>Table 1. FDA Sample Results- Finished Products Collected from E Cedar Street Facility\u003C\u002Fem>\u003C\u002Fp>\u003Cdiv>\u003Ctable>\u003Ctbody>\u003Ctr>\u003Ctd>\u003Cstrong>FDA Sample #\u002FProduct\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>\u003Cstrong>pH (original)\u002FpH (check)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>\u003Cstrong>L. monocytogenes growth supported?\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>\u003Cstrong>C. botulinum growth supported?\u003C\u002Fstrong>\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>1317729\u002F\u003Cbr>PAD THAI Rice Stick Noodle 1lb, Lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>4.59 to 4.75\u002F\u003Cbr>4.55 to 4.63\u003C\u002Ftd>\u003Ctd>Yes, pH &gt; 4.4\u003C\u002Ftd>\u003Ctd>No, however, the pH is above your firm’s target pH of \u003Cstrong>(b)(4)\u003C\u002Fstrong> at \u003Cstrong>(b)(4)\u003C\u002Fstrong> for finished products.\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>1317730\u002F\u003Cbr>FRESH RICE STICK NOODLE BANH PHO TUOI, 1lb Lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>4.58 to 4.78\u002F\u003Cbr>4.64 to 4.91\u003C\u002Ftd>\u003Ctd>Yes, pH &gt;4.4\u003C\u002Ftd>\u003Ctd>Yes, the pH was as high as 4.91 in the check analysis, and it exceeds your firm’s target pH of \u003Cstrong>(b)(4)\u003C\u002Fstrong> at \u003Cstrong>(b)(4)\u003C\u002Fstrong> for finished products.\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>1317732\u002F\u003Cbr>RICE STICK NOODLE BIG CUT NOODLE 10 lbs., Lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>4.55 to 4.61\u002F\u003Cbr>4.55 to 4.64\u003C\u002Ftd>\u003Ctd>Yes, pH &gt; 4.4\u003C\u002Ftd>\u003Ctd>No, however, the pH is above your firm’s target pH of \u003Cstrong>(b)(4)\u003C\u002Fstrong> at \u003Cstrong>(b)(4)\u003C\u002Fstrong> for finished products.\u003C\u002Ftd>\u003C\u002Ftr>\u003C\u002Ftbody>\u003C\u002Ftable>\u003C\u002Fdiv>\u003Cp>*Note: The water activity values were above 0.85 in the RTE rice noodle samples analyzed by FDA (water activity values ranged from 0.98 to 1.00).\u003C\u002Fp>\u003Cp>Additionally, your temperature check control mechanism does not appear to provide adequate control for the finished product stage. For example, during the inspection our investigators observed the following:\u003C\u002Fp>\u003Cul>\u003Cli>On January 28, 2026, our investigators measured temperatures between two bags from two different locations on a pallet of finished product Banh Pho Tuoi noodles, Lot \u003Cstrong>(b)(4)\u003C\u002Fstrong> (\u003Cstrong>(b)(4)\u003C\u002Fstrong> plastic ROP, \u003Cstrong>(b)(4)\u003C\u002Fstrong> per box), at 52°F and 53.5°F while stored in the cooler. The noodles had been cut and packaged on \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and visible condensate was observed inside the finished product packaging.\u003C\u002Fli>\u003Cli>On January 28, 2026, our investigators measured the temperature between two bags of finished product Pad Thai noodles, Lot \u003Cstrong>(b)(4)\u003C\u002Fstrong> (\u003Cstrong>(b)(4)\u003C\u002Fstrong> plastic ROP, \u003Cstrong>(b)(4)\u003C\u002Fstrong> per box), at 70.5°F while stored in the cooler. The noodles had been cut and packaged on \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and visible condensate was observed inside the finished product packaging.\u003C\u002Fli>\u003Cli>On February 12, 2026, cooked, in-process rice noodle sheets from Lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>, held \u003Cstrong>(b)(4)\u003C\u002Fstrong> Lines \u003Cstrong>(b)(4)\u003C\u002Fstrong>, were observed stored at \u003Cstrong>(b)(4)\u003C\u002Fstrong> temperature. At 9:40 AM, our investigators measured the rice noodle sheet temperatures at 82°F, 77°F, and 81°F, respectively. At 3:32 PM, our investigators measured the rice noodle sheet temperatures at 79.5°F, 73°F, and 73°F, respectively. The rice noodle sheets remained at \u003Cstrong>(b)(4)\u003C\u002Fstrong> temperature \u003Cstrong>(b)(4)\u003C\u002Fstrong> until cut into individual noodles and packaged as Banh Pho Tuoi (10 lb.), Lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>, at approximately 5:30 AM and placed in the refrigerator at approximately 6:00 AM on February 13, 2026. At 9:13 AM on February 13, 2026, our investigators measured the temperature of a finished RTE 10 lb. ROP bag of Banh Pho Tuoi rice noodles in the refrigerator at 61°F.\u003C\u002Fli>\u003Cli>On February 23, 2026, our investigators measured the temperature between two bags of finished Banh Pho Tuoi noodles, Lot 04-23-A1 (10 lb. bags, \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4) \u003C\u002Fstrong>closed, \u003Cstrong>(b)(4)\u003C\u002Fstrong> bags per box), at 78.5°F at 9:10 AM. These products were placed in the cooler at approximately 9:05 AM. At 3:18 PM, our investigators measured the temperatures between the bags of finished rice noodles at 74.5°F. On February 24, 2026, at 11:10 AM, our investigators measured the temperature between the bags of finished rice noodles at 66.5°F. After 26 hours of refrigerator storage, the product had cooled by only 12°F.\u003C\u002Fli>\u003Cli>Packaged finished products from your firm’s S Parco Avenue facility are also stored at your E Cedar Street facility until distribution. On February 23, 2026, our investigators measured the temperature between two bags of finished Banh Pho Tuoi noodles, Lot 04-23-B1 (\u003Cstrong>(b)(4)\u003C\u002Fstrong> bags, \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> closed, \u003Cstrong>(b)(4)\u003C\u002Fstrong> bags per box), from the S Parco Avenue facility at 66.5°F at 9:10 AM. These products were placed in your E Cedar Street facility cooler at approximately 9:00 AM. At 3:18 PM, our investigators measured the temperatures between the bags of finished rice noodles at 66°F. On February 24, 2026, at 11:10 AM, our investigators measured the temperature between the bags of finished rice noodles at 62°F. After 26 hours of refrigerated storage, the finished product had cooled by only 4.5°F.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Your FDA-483 response included an updated process preventive control of testing the pH of \u003Cstrong>(b)(4)\u003C\u002Fstrong>; however, we are unable to fully evaluate the response because it is unclear whether \u003Cstrong>(b)(4)\u003C\u002Fstrong> samples is representative of the entire batch of approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> of rice noodles. Moreover, a pH of \u003Cstrong>(b)(4)\u003C\u002Fstrong> alone may not be adequate for Listeria control. FDA recommends referencing Appendix 3, Table 3-A of our \u003Cu>Draft Guidance for Industry: Hazard Analysis and Risk-Based Preventive Controls for Human Food\u003C\u002Fu>, which outlines the limiting conditions for \u003Cem>L. monocytogenes\u003C\u002Fem> growth. Additionally, your written response does not account for when the temperature of the RTE packaged rice noodles are not monitored during storage in the cooler before they are shipped, which can allow for pathogen growth and\u002For toxin formation in the finished product due to extended exposure to elevated temperatures over time. Your practice of not releasing product for shipment until it is \u003Cstrong>(b)(4)\u003C\u002Fstrong> does not provide adequate control for this hazard. As previously mentioned, most foodborne bacteria and bacterial spores can survive refrigeration, and some relevant organisms can continue growing at or below \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>We acknowledge receipt of certificates of destruction for your voluntary destruction of in-process and finished products as part of the corrective actions taken by your firm in response to these observations.\u003C\u002Fp>\u003Cp>2. Your written sanitation preventive controls did not include procedures, practices, and processes to ensure that the facility is maintained in a sanitary condition adequate to significantly minimize or prevent hazards such as environmental pathogens and biological hazards due to employee handling, to comply with 21 CFR 117.135(c)(3).\u003C\u002Fp>\u003Cp>Your food safety plan listed the hazard of “Biological” and an associated sanitation preventive control of “Cleaning of equipment and utensils.” However, your cleaning practices for your food contact equipment after the \u003Cstrong>(b)(4)\u003C\u002Fstrong> step are not adequate to significantly minimize or prevent hazards given the infrequent nature of the cleaning. More specifically, during the inspection, our investigators observed that you use cut machines \u003Cstrong>(b)(4)\u003C\u002Fstrong>, noodle trays \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and cut tables \u003Cstrong>(b)(4)\u003C\u002Fstrong> for daily production\u003Cbr>runs, but the cleaning and sanitation is completed on a rotating basis, so equipment is cleaned and sanitized only \u003Cstrong>(b)(4)\u003C\u002Fstrong>. This frequency does not ensure that the facility is maintained in a sanitary condition adequate to significantly minimize or prevent hazards given that your RTE rice noodle sheets and RTE cut rice noodles are exposed to the environment after being \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> handled by employees prior to being packaged, where they may be contaminated with environmental pathogens, such as \u003Cem>L. monocytogenes\u003C\u002Fem> and other pathogens due to poor sanitation and employee practices. We also note that the \u003Cstrong>(b)(4)\u003C\u002Fstrong> sheets used in direct contact with stacked RTE rice noodle sheets during drying\u002Fcuring were not being cleaned and sanitized at all. These sheets were observed with discoloration, and some sheets had frayed edges as well.\u003C\u002Fp>\u003Cp>Your response to the FDA-483 indicated you have updated your sanitation preventive controls by including personnel handwashing and an “EMP program” as new components. Your response also described a new equipment wipe down practice using \u003Cstrong>(b)(4)\u003C\u002Fstrong> in your Cutting\u002FPacking Department and Noodle Receiving area at the \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and you noted that cleaning of electric fans and \u003Cstrong>(b)(4)\u003C\u002Fstrong> sheets are included in the wipe down activity for the Noodle Receiving area. We will evaluate the adequacy of your corrective actions during our next inspection.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>S Parco Avenue Facility\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>3. You did not prepare, or have prepared, and implement a food safety plan, as required by 21 CFR 117.126(a)(1). Your food safety plan must include the following:\u003C\u002Fp>\u003Cp>1) The written hazard analysis, as required by § 117.130(a)(2);\u003Cbr>2) The written preventive controls, as required by § 117.135(b);\u003Cbr>3) The written supply‐chain program, as required by subpart G;\u003Cbr>4) The written recall plan, as required by § 117.139(a);\u003Cbr>5) The written procedures for monitoring the implementation of the preventive controls, as required by § 117.145(a);\u003Cbr>6) The written corrective action procedures, as required by § 117.150(a)(1); and\u003Cbr>7) The written verification procedures, as required by § 117.165(b).\u003C\u002Fp>\u003Cp>Your facility manufactures refrigerated RTE rice noodles in ROP packaging. However, you did not have a food safety plan with any of the required elements for these products. For example, you did not conduct a hazard analysis to identify and evaluate known or reasonably foreseeable hazards for RTE rice noodles manufactured and packaged at your facility to determine whether there are any hazards requiring a preventive control, as required by 21 CFR 117.130(a). Also, you did not identify and implement preventive controls to provide assurances that any hazards requiring a preventive control will be significantly minimized or prevented and the food manufactured, processed, packed, or held by your facility will not be adulterated under section 402 of the Act [see 21 CFR 117.135(a)(1)]. Preventive controls include, as appropriate to the facility and the food, process controls, food allergen controls, sanitation controls, supply-chain controls, and a recall plan [see 21 CFR 117.135(c)]. Preventive controls are subject to preventive control management components (monitoring, verification, and corrective actions) as appropriate to ensure the effectiveness of the preventive controls, taking into account the nature of the preventive control and its role in the facility's food safety system (see 21 CFR 117.140).\u003C\u002Fp>\u003Cp>For example, you did not identify growth and survival of bacterial pathogens, such as \u003Cem>B. cereus, L. monocytogenes\u003C\u002Fem>, and \u003Cem>C. botulinum\u003C\u002Fem> as known or reasonably foreseeable hazards to determine whether they are hazards requiring a preventive control. Your in-process and finished ROP rice noodles are produced without time-temperature and\u002For \u003Cstrong>(b)(4)\u003C\u002Fstrong> and are likely to support the growth of bacterial pathogens and\u002For toxin formation. A knowledgeable person manufacturing\u002Fprocessing food in your circumstances would identify growth of bacterial pathogens as a hazard requiring a preventive control (e.g., process controls). Process controls include procedures, practices, and processes to ensure the control of parameters during operations. Where appropriate, process controls must also include the parameters associated with the control of the hazard and the minimum and\u002For maximum values needed to significantly minimize or prevent the hazards requiring a process control [see 21 CFR 117.135(c)(1)].\u003C\u002Fp>\u003Cp>During the inspection, FDA investigators observed the following instances of time-temperature abuse of the RTE rice noodles:\u003C\u002Fp>\u003Cul>\u003Cli>On February 11, 2026, our investigators measured the temperature of cooked in-process RTE Banh Pho Tuoi rice noodle sheets, Lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>, during the \u003Cstrong>(b)(4)\u003C\u002Fstrong> process on Lines \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> at 9:00 AM at 69°F and 66.5°F, respectively. The rice noodle sheets were stacked \u003Cstrong>(b)(4)\u003C\u002Fstrong> sheets in stacks approximately four feet high with a \u003Cstrong>(b)(4)\u003C\u002Fstrong> of each stack. At 10:14 AM the temperature of the rice noodle sheets was measured at 71.5°F and 64.5°F; at 12:19 PM the temperature was measured at 69°F and 65°F; and at 3:20 PM, was measured at 69°F and 66°F.\u003C\u002Fli>\u003Cli>The cut noodles are packed in 10 lb. bags with the \u003Cstrong>(b)(4)\u003C\u002Fstrong> removed and \u003Cstrong>(b)(4)\u003C\u002Fstrong> closed creating the potential for ROP conditions within the bag due to the permeability of the packaging material. The bags are packed in cases, the cases are palletized and wrapped in plastic wrap, and the pallets are transferred from the S Parco facility to the refrigerator at the E Cedar facility before being fully cooled. As noted in the E Cedar facility observations above, Lot 04-23-B1 of Banh Pho Tuoi noodles cooled by only 4.5°F over 26 hours (from 66.5°F to 62°F).\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Further, FDA sample (#1317731) of refrigerated FRESH RICE STICK NOODLE BANH PHO TUOI (10 lbs., Lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>) was collected and analyzed for pH and water activity. The finished product was found to have a pH range of 4.67 to 4.93 (original analysis) and 4.52 to 4.64 (check analysis). The water activity was found to be 1.0 (original analysis) and 0.99 (check analysis). These pH and water activity values may allow for bacterial pathogen growth and toxin formation.\u003C\u002Fp>\u003Cp>Additionally, you did not identify recontamination with environmental pathogens, such as \u003Cem>L. monocytogenes\u003C\u002Fem>, as a known or reasonably foreseeable hazard to determine whether it is a hazard requiring a preventive control. Your RTE rice noodles are exposed to the environment after being \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> dried and then \u003Cstrong>(b)(4)\u003C\u002Fstrong> by employees prior to packaging. The packaged noodles do not receive a lethal treatment or otherwise include another control that would significantly minimize the hazard of recontamination with environmental pathogens.\u003C\u002Fp>\u003Cp>Contamination with environmental pathogens is a known or reasonably foreseeable hazard. A knowledgeable person manufacturing\u002Fprocessing food in your circumstances would identify contamination with environmental pathogens as a hazard requiring a preventive control (e.g., sanitation controls). Sanitation controls include procedures, practices, and processes to ensure that the facility is maintained in a sanitary condition adequate to significantly minimize or prevent hazards such as environmental pathogens and biological hazards due to employee handling [see 21 CFR 117.135(c)(3)]. In addition, we note that verification activities must include, as appropriate, environmental monitoring if contamination of an RTE food with an environmental pathogen is a hazard requiring a preventive control [see 21 CFR 117.165(a)(3)].\u003C\u002Fp>\u003Cp>Your firm’s FDA-483 response dated March 17, 2026 provided a hazard analysis and preventive controls and an environmental monitoring program. We acknowledge that you intend to use pH, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and temperature controls to ensure the safety of your finished RTE rice noodle products. However, your process preventive controls for the manufacturing of RTE rice noodles at your S Parco Avenue facility appear to be the same as those provided for your E Cedar Street facility. Accordingly, FDA has the same concerns regarding inadequate controls for bacterial pathogen growth and\u002For toxin formation as those discussed above for the E Cedar Street facility. We also note that the food safety plan, dated March 9, 2026 included in your FDA-483 response did not include a written recall plan as required.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Current Good Manufacturing Practice (21 CFR Part 117, Subpart B):\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>E Cedar Street Facility\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>1. Your plant was not constructed in such a manner that drip or condensate from fixtures, ducts and pipes does not contaminate food and food-contact surfaces, as required by 21 CFR 117.20(b)(4). Specifically, on January 27, 2026, during the manufacturing of RTE rice noodle sheets (Lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>), continuous \u003Cstrong>(b)(4)\u003C\u002Fstrong> around the \u003Cstrong>(b)(4)\u003C\u002Fstrong> vent hoods on \u003Cstrong>(b)(4)\u003C\u002Fstrong> Lines \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> were observed, with condensate collecting on the edge of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> exhaust hoods directly over exposed noodle sheets. Condensate was observed to drip from the hood surface which is located at the \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The exterior surface of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> hood on Line \u003Cstrong>(b)(4)\u003C\u002Fstrong> was observed with rust-like discoloration on the outer hood surface where condensate was forming.\u003C\u002Fp>\u003Cp>Your response to the FDA-483 indicated that the \u003Cstrong>(b)(4)\u003C\u002Fstrong> vent hood was thoroughly cleaned and sanitized to prevent condensation and to remove rust. Your response is not adequate because it does not address how you would prevent condensate from forming and serving as a potential contaminant to food-contact surfaces and to your RTE rice noodle products \u003Cstrong>(b)(4)\u003C\u002Fstrong> the \u003Cstrong>(b)(4)\u003C\u002Fstrong> in the future.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>S Parco Avenue Facility\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>2. You did not clean and sanitize your utensils and equipment in a manner that protects against contamination of food-contact surfaces, as required by 21 CFR 117.35(a). During cleaning and sanitation operations on January 29, 2026 in your S Parco facility, FDA investigators observed employees cleaning soiled equipment in a manner that caused overspray to contact food-contact surfaces of equipment that had already been cleaned.\u003C\u002Fp>\u003Cp>Your response to the FDA-483 indicated that personnel were trained to avoid recontamination of cleaned equipment by avoiding splashing water. We will evaluate the adequacy of your corrective action during the next inspection of your facility.\u003C\u002Fp>\u003Cp>3. You did not take effective measures to exclude pests from the manufacturing, processing, packing, and holding areas of your facility to protect against contamination of food, as required by 21 CFR 117.35(c). Specifically,\u003C\u002Fp>\u003Cp>a. On January 27, 2026, during the manufacturing of RTE Banh Pho Tuoi rice noodles (Lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>), at least five apparent dead black winged insects were observed in \u003Cstrong>(b)(4)\u003C\u002Fstrong> and one bee-like insect was observed on the dispensing table adjacent to the \u003Cstrong>(b)(4) \u003C\u002Fstrong>bulk tote. Two live black winged insects were observed on a \u003Cstrong>(b)(4)\u003C\u002Fstrong> bag holding rice.\u003C\u002Fp>\u003Cp>b. On February 5, 2026, during the manufacturing of RTE Banh Pho Tuoi rice noodles (Lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>), two dead apparent cockroaches were observed in the facility. One insect was observed in the drain between the rice noodle \u003Cstrong>(b)(4)\u003C\u002Fstrong> lines, and one was observed between pallets of raw rice.\u003C\u002Fp>\u003Cp>Your response to the FDA-483 addressed actions taken by your pest control company to treat for cockroaches and actions you have taken to prevent their entry into the facility. An employee training record covering the requirement for personnel to report pest sightings in the production facility was also provided and focused on cockroaches and mouse\u002Frat activity. We note that the \u003Cstrong>(b)(4)\u003C\u002Fstrong> rice observed in contact with dead black winged insects was voluntarily discarded on January 27, 2026, following identification of this condition. We will evaluate the adequacy of your corrective actions during the next inspection.\u003C\u002Fp>\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist at your facility or in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including applicable FDA regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>We also offer the following comments:\u003C\u002Fp>\u003Cul>\u003Cli>On February 3, 2026, FDA collected environmental swabs (FDA sample #1309377) from your E Cedar Street facility. Two (2) swabs collected from a \u003Cstrong>(b)(4)\u003C\u002Fstrong> tested positive for \u003Cem>Listeria grayi\u003C\u002Fem>. This \u003Cstrong>(b)(4)\u003C\u002Fstrong> was approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> area and approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fli>\u003Cli>On February 10, 2026, FDA collected environmental swabs (FDA sample #1322596) from your S Parco Avenue facility. Two (2) swabs tested positive for \u003Cem>Listeria innocua\u003C\u002Fem> (including the food contact surface of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> above the \u003Cstrong>(b)(4)\u003C\u002Fstrong> and the \u003Cstrong>(b)(4)\u003C\u002Fstrong> and two (2) locations were positive for \u003Cem>Listeria grayi\u003C\u002Fem> \u003Cstrong>(b)(4)\u003C\u002Fstrong> on the \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>These findings can be an indicator of inadequate sanitation and of conditions that support the growth of Listeria monocytogenes (a human pathogen) in your manufacturing facilities.\u003C\u002Fp>\u003Cul>\u003Cli>We acknowledge the presence of cooking instructions on your product labeling and your work in establishing the adequacy of these instructions, however your rice noodles are a RTE food as it is reasonably foreseeable that your fully cooked rice noodles will be eaten without further processing that would significantly minimize biological hazards based on how consumers use your product.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Please notify FDA in writing, within fifteen (15) working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within fifteen (15) working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>Please send your reply to: HFP-OCE-ConventionalFoods@fda.hhs.gov, copying Valerie Potopsingh, Compliance Officer at valerie.potopsingh@fda.hhs.gov or by hardcopy to Food and Drug Administration, Attention: Valerie Potopsingh, Compliance Officer, Human Foods Program – Office of Compliance and Enforcement, Office of Enforcement – Division of Conventional Foods Enforcement (HFS-607), 5001 Campus Drive, College Park, MD 20740. If you have any questions regarding this letter, you may contact Valerie Potopsingh, Compliance Officer, via email at valerie.potopsingh@fda.hhs.gov. Please include reference CMS #730689 on any submissions and within the subject line of any email correspondence to the agency.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Maria S. Knirk, JD MBA\u003Cbr>Director\u003Cbr>Office of Enforcement\u003Cbr>Office of Compliance and Enforcement\u003Cbr>Human Foods Program\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA ELECTRONIC DELIVERY\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nMs. Karen Ving, President\n\nRecipient Title\n\nMr. Jonathan Ving, General Manager\n\nRama Food Manufacture Corp.\n\n1486 E Cedar Street\n\nOntario, CA 91761-8300\n\nUnited States\n\nJonathan.Ving@ramafood.com\n\nIssuing Office:\n\nHuman Foods Program\n\nUnited States\n\nSeptember 22, 2026\nWARNING LETTER\nRe: CMS #730689\nDear Ms. Ving and Mr. Ving:\nThe United States Food and Drug Administration (FDA) inspected two of your Rama Food Manufacture Corp. food manufacturing facilities located at 1486 E Cedar Street, Ontario, California 91761 and 2131 S Parco Avenue, Ontario, California 91761 from January 27 through February 26, 2026. Both facilities manufacture ready-to-eat (RTE) rice noodles (various noodle sizes\u002Ftypes).\nDuring our inspections, FDA investigators observed serious violations of the Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Human Food regulation (CGMP & PC rule), Title 21, Code of Federal Regulations, Part 117 (21 CFR Part 117). Additionally, FDA collected environmental samples (i.e., swabs) from various areas in both facilities. FDA laboratory analysis of the environmental swabs found the presence of Listeria innocua and grayi in your S Parco Avenue facility and L. grayi in your E Cedar Street facility, which are non-human pathogenic Listeria spp. FDA also collected four finished product samples and analyzed them for water activity and pH.\nBased on FDA’s inspectional findings and analytical results for finished product samples of Pad Thai Rice Stick Noodle, Fresh Rice Stick Noodle Banh Pho Tuoi, and Rice Stick Noodle Big Cut Noodle, we have determined that the RTE rice noodle products manufactured in both of your facilities are adulterated within the meaning of section 402(a)(4) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 342(a)(4)] because they were prepared, packed, or held under insanitary conditions whereby they may have become contaminated with filth or been rendered injurious to health. In addition, failure of the owner, operator, or agent in charge of a covered facility to comply with the preventive control provisions of the CGMP & PC rule (located in subparts A, C, D, E, F, and G of Part 117) is prohibited by section 301(uu) of the Act [21 U.S.C. § 331(uu)]. You may find the Act and further information about the CGMP & PC rule through links on FDA’s website at http:\u002F\u002Fwww.fda.gov.\nAt the conclusion of both inspections, the FDA investigators issued a Form FDA 483 (FDA-483), Inspectional Observations to each facility. We received your written responses to both FDA-483s on March 17, 2026, describing your planned and implemented corrective actions. Based on our review of the inspectional and analytical findings and your responses, we are issuing this letter to advise you of FDA’s continuing concerns and to provide detailed information describing the findings at each of your facilities. We discuss your responses below.\nHazard Analysis and Risk-Based Preventive Controls (21 CFR Part 117, Subpart C):\nE Cedar Street Facility\n1. Your written process preventive control procedures were not appropriate to significantly minimize or prevent hazards requiring preventive controls, as required by 21 CFR 117.135(c)(1). Your facility’s written hazard analysis determined that pathogen hazards such as Bacillus cereus (B. cereus), Salmonella, Listeria monocytogenes (L. monocytogenes), and Clostridium botulinum (C. botulinum) required a preventive control. The “Preventive Controls” section of your food safety plan document indicates that such hazards will be significantly minimized or prevented at the rice (b)(4) to rice (b)(4), rice (b)(4), (b)(4), and (b)(4) processing steps. However, a review of your established control methods\u002Fcritical limits for these process preventive controls determined that they may not control the hazards. Additionally, in some cases, monitoring of these parameters was not implemented and\u002For the parameters were not met. Specifically,\na. (b)(4): Your “Temperature Control of Rice (b)(4) Tank” process preventive control covering rice (b)(4) to rice (b)(4) in your food safety plan lists a critical limit of “Rice (b)(4) Temperature ≤ (b)(4)” to be checked “Every (b)(4)” which does not provide sufficient control for the hazard of B. cereus identified at these processing steps. If the (b)(4) rice is exposed to temperatures above 70°F for more than three hours cumulatively, pathogens such as B. cereus can grow and produce toxin. FDA recommends referencing Appendix 3, Table 3-B of our Draft Guidance for Industry: Hazard Analysis and Risk-Based Preventive Controls for Human Food, which explains that for the potential hazardous conditions of growth and toxin formation of B. cereus, the recommended maximum cumulative exposure time for product temperatures above 70°F is three hours.\nYour response to the FDA-483 dated March 17, 2026, included updated time and temperature critical limits for the process preventive control covering the rice (b)(4) and rice (b)(4) steps (b)(4). As written, your critical limits of (b)(4) process ≤ (b)(4) rice temperature ≤ (b)(4), (b)(4) process ≤ (b)(4), and (b)(4) rice temperature ≤ (b)(4) would still allow the soaked and ground rice to be exposed to temperatures above 70°F for up to 3.5 hours cumulatively, which does not appear to provide adequate control for the hazard of B. cereus. Your response also referenced a proposed challenge study as the basis for these critical limits and stated that the results of the study would be provided upon completion. To date, you have not provided additional information to the Agency regarding this issue.\nb. (b)(4): Your “pH Control of Rice (b)(4)” process preventive control (b)(4) in your food safety plan lists a critical limit of “Rice (b)(4)” which may not provide sufficient control for the hazard of pathogen growth and toxin formation, such as B. cereus, identified at this processing step. Your firm stated that (b)(4) were also added to control for B. cereus; however, you had no written process preventive control for the addition of (b)(4). The rice (b)(4) is (b)(4) before being (b)(4) and packaged, exposing the noodles to elevated temperatures for extended periods of time which may allow for the growth of pathogens and\u002For toxin formation, such as B. cereus.\nOn February 12, 2026, our investigators measured the temperature of in-process RTE rice noodle sheets, Lot (b)(4), from Lines (b)(4) and (b)(4) at the (b)(4) step at (b)(4) and (b)(4) around 9:20 AM. After (b)(4), the rice noodle sheets were (b)(4) approximately (b)(4). A (b)(4) was placed on the stacked sheets, and a fan was blowing on the rice sheets during the (b)(4) process. At 10:38 AM, the rice noodle sheet temperature measured at 87°F and 87.5°F. At 3:30 PM, our investigators measured the rice noodle sheet temperatures from each line at 80°F and 81.5°F, respectively. The temperatures of rice noodle sheets were above 70°F for 6 hours and 10 minutes when this process was observed during the inspection.\nYour response to the FDA-483 indicated the use of pH control and (b)(4) in the rice (b)(4) to control for the hazards of B. cereus and C. perfringens at “(b)(4).” However, the letter you provided from (b)(4) noted “A product-specific validation (e.g. (b)(4)) for B. cereus is recommended to specifically support the Food Safety Plan for its control in the noodle process.” You indicated that you were planning a validation study for product (b)(4) with your microbiological consultant and that you would submit the results once completed. To date, you have not provided such a validation study to the Agency.\nAdditionally, we note that you have not identified the cooling of the cooked rice noodle sheets (b)(4) as requiring a process preventive control and have not implemented monitoring procedures to ensure the RTE rice noodle sheets are cooled quickly enough to adequately control bacterial growth and\u002For toxin formation during cooling. FDA recommends in the Food Code cooling from 57ºC (135ºF) to 21ºC (70°F) within 2 hours and then further cooling to 5ºC (41°F) within a total of six hours. The cooling time to reduce temperatures to 21ºC (70°F) is important to ensure products are cooled quickly through the optimum temperatures for growth of bacterial pathogens. Your response to the FDA-483 indicates that you intend the rice (b)(4) pH check and (b)(4) to provide adequate control for B. cereus growth and\u002For toxin formation through the noodle cooling and drying process. However, as noted above, you have not provided the results of the planned validation study referenced in your response.\nc. (b)(4): Your “(b)(4)” process preventive control (b)(4) in your food safety plan lists temperature checks and pH checks as control mechanisms for pathogen growth [L. monocytogenes and C. botulinum in (b)(4). For temperature checks, you list a method of “Check Finished Product temperature ((b)(4)) ≤ (b)(4)” with a frequency of “(b)(4)”. Your finished RTE rice noodles are packaged before (b)(4) without the product temperature being monitored. Most foodborne bacteria and bacterial spores can survive refrigeration, and some relevant organisms can continue growing at or below 40°F. For pH checks you list a method of “Check Finished Product pH ≤ (b)(4)” with a frequency of “(b)(4)”. (b)(4) ≤ (b)(4) alone may not be adequate for Listeria control and your products were observed to be exposed to temperatures above 40°F for extended periods of time during finished product storage after packaging, which can allow for the growth of L. monocytogenes.\nAdditionally, FDA’s sampling results for your finished rice noodle products demonstrate that you do not consistently meet your critical limit of a pH (b)(4) in finished products (refer to Table 1 below). Also, you check the pH of (b)(4), which is not representative of the entire lot of approximately (b)(4) of rice noodles.\nYour firm packages RTE rice noodles (various noodle sizes\u002Ftypes) in 1 lb. reduced oxygen packaging (ROP), in (b)(4) lb. (b)(4) film packaging, and in (b)(4) lb. packaging where (b)(4) is (b)(4) from the package and bags are (b)(4) closed (the latter two may create ROP conditions due to permeability of the packaging material). This creates anaerobic conditions that can allow for C. botulinum growth and toxin formation in the absence of adequate product pH and temperature controls. Your control method of a finished product pH of (b)(4) may provide adequate control for the hazard of C. botulinum at this processing step if properly implemented. However, FDA collected finished product samples from your E Cedar Street facility for pH and water activity analysis. The analysis found that your process did not consistently yield a finished product pH (b)(4) in accordance with the critical limit established by your firm. The results are summarized in the table below:\nTable 1. FDA Sample Results- Finished Products Collected from E Cedar Street Facility\nFDA Sample #\u002FProductpH (original)\u002FpH (check)L. monocytogenes growth supported?C. botulinum growth supported?\n1317729\u002F\nPAD THAI Rice Stick Noodle 1lb, Lot (b)(4)4.59 to 4.75\u002F\n4.55 to 4.63Yes, pH > 4.4No, however, the pH is above your firm’s target pH of (b)(4) at (b)(4) for finished products.\n1317730\u002F\nFRESH RICE STICK NOODLE BANH PHO TUOI, 1lb Lot (b)(4)4.58 to 4.78\u002F\n4.64 to 4.91Yes, pH >4.4Yes, the pH was as high as 4.91 in the check analysis, and it exceeds your firm’s target pH of (b)(4) at (b)(4) for finished products.\n1317732\u002F\nRICE STICK NOODLE BIG CUT NOODLE 10 lbs., Lot (b)(4)4.55 to 4.61\u002F\n4.55 to 4.64Yes, pH > 4.4No, however, the pH is above your firm’s target pH of (b)(4) at (b)(4) for finished products.\n\n*Note: The water activity values were above 0.85 in the RTE rice noodle samples analyzed by FDA (water activity values ranged from 0.98 to 1.00).\nAdditionally, your temperature check control mechanism does not appear to provide adequate control for the finished product stage. For example, during the inspection our investigators observed the following:\nOn January 28, 2026, our investigators measured temperatures between two bags from two different locations on a pallet of finished product Banh Pho Tuoi noodles, Lot (b)(4) ((b)(4) plastic ROP, (b)(4) per box), at 52°F and 53.5°F while stored in the cooler. The noodles had been cut and packaged on (b)(4), and visible condensate was observed inside the finished product packaging.\nOn January 28, 2026, our investigators measured the temperature between two bags of finished product Pad Thai noodles, Lot (b)(4) ((b)(4) plastic ROP, (b)(4) per box), at 70.5°F while stored in the cooler. The noodles had been cut and packaged on (b)(4), and visible condensate was observed inside the finished product packaging.\nOn February 12, 2026, cooked, in-process rice noodle sheets from Lot (b)(4), held (b)(4) Lines (b)(4), were observed stored at (b)(4) temperature. At 9:40 AM, our investigators measured the rice noodle sheet temperatures at 82°F, 77°F, and 81°F, respectively. At 3:32 PM, our investigators measured the rice noodle sheet temperatures at 79.5°F, 73°F, and 73°F, respectively. The rice noodle sheets remained at (b)(4) temperature (b)(4) until cut into individual noodles and packaged as Banh Pho Tuoi (10 lb.), Lot (b)(4), at approximately 5:30 AM and placed in the refrigerator at approximately 6:00 AM on February 13, 2026. At 9:13 AM on February 13, 2026, our investigators measured the temperature of a finished RTE 10 lb. ROP bag of Banh Pho Tuoi rice noodles in the refrigerator at 61°F.\nOn February 23, 2026, our investigators measured the temperature between two bags of finished Banh Pho Tuoi noodles, Lot 04-23-A1 (10 lb. bags, (b)(4) and (b)(4) closed, (b)(4) bags per box), at 78.5°F at 9:10 AM. These products were placed in the cooler at approximately 9:05 AM. At 3:18 PM, our investigators measured the temperatures between the bags of finished rice noodles at 74.5°F. On February 24, 2026, at 11:10 AM, our investigators measured the temperature between the bags of finished rice noodles at 66.5°F. After 26 hours of refrigerator storage, the product had cooled by only 12°F.\nPackaged finished products from your firm’s S Parco Avenue facility are also stored at your E Cedar Street facility until distribution. On February 23, 2026, our investigators measured the temperature between two bags of finished Banh Pho Tuoi noodles, Lot 04-23-B1 ((b)(4) bags, (b)(4) and (b)(4) closed, (b)(4) bags per box), from the S Parco Avenue facility at 66.5°F at 9:10 AM. These products were placed in your E Cedar Street facility cooler at approximately 9:00 AM. At 3:18 PM, our investigators measured the temperatures between the bags of finished rice noodles at 66°F. On February 24, 2026, at 11:10 AM, our investigators measured the temperature between the bags of finished rice noodles at 62°F. After 26 hours of refrigerated storage, the finished product had cooled by only 4.5°F.\nYour FDA-483 response included an updated process preventive control of testing the pH of (b)(4); however, we are unable to fully evaluate the response because it is unclear whether (b)(4) samples is representative of the entire batch of approximately (b)(4) of rice noodles. Moreover, a pH of (b)(4) alone may not be adequate for Listeria control. FDA recommends referencing Appendix 3, Table 3-A of our Draft Guidance for Industry: Hazard Analysis and Risk-Based Preventive Controls for Human Food, which outlines the limiting conditions for L. monocytogenes growth. Additionally, your written response does not account for when the temperature of the RTE packaged rice noodles are not monitored during storage in the cooler before they are shipped, which can allow for pathogen growth and\u002For toxin formation in the finished product due to extended exposure to elevated temperatures over time. Your practice of not releasing product for shipment until it is (b)(4) does not provide adequate control for this hazard. As previously mentioned, most foodborne bacteria and bacterial spores can survive refrigeration, and some relevant organisms can continue growing at or below (b)(4).\nWe acknowledge receipt of certificates of destruction for your voluntary destruction of in-process and finished products as part of the corrective actions taken by your firm in response to these observations.\n2. Your written sanitation preventive controls did not include procedures, practices, and processes to ensure that the facility is maintained in a sanitary condition adequate to significantly minimize or prevent hazards such as environmental pathogens and biological hazards due to employee handling, to comply with 21 CFR 117.135(c)(3).\nYour food safety plan listed the hazard of “Biological” and an associated sanitation preventive control of “Cleaning of equipment and utensils.” However, your cleaning practices for your food contact equipment after the (b)(4) step are not adequate to significantly minimize or prevent hazards given the infrequent nature of the cleaning. More specifically, during the inspection, our investigators observed that you use cut machines (b)(4), noodle trays (b)(4), and cut tables (b)(4) for daily production\nruns, but the cleaning and sanitation is completed on a rotating basis, so equipment is cleaned and sanitized only (b)(4). This frequency does not ensure that the facility is maintained in a sanitary condition adequate to significantly minimize or prevent hazards given that your RTE rice noodle sheets and RTE cut rice noodles are exposed to the environment after being (b)(4) and (b)(4) and (b)(4) handled by employees prior to being packaged, where they may be contaminated with environmental pathogens, such as L. monocytogenes and other pathogens due to poor sanitation and employee practices. We also note that the (b)(4) sheets used in direct contact with stacked RTE rice noodle sheets during drying\u002Fcuring were not being cleaned and sanitized at all. These sheets were observed with discoloration, and some sheets had frayed edges as well.\nYour response to the FDA-483 indicated you have updated your sanitation preventive controls by including personnel handwashing and an “EMP program” as new components. Your response also described a new equipment wipe down practice using (b)(4) in your Cutting\u002FPacking Department and Noodle Receiving area at the (b)(4), and you noted that cleaning of electric fans and (b)(4) sheets are included in the wipe down activity for the Noodle Receiving area. We will evaluate the adequacy of your corrective actions during our next inspection.\nS Parco Avenue Facility\n3. You did not prepare, or have prepared, and implement a food safety plan, as required by 21 CFR 117.126(a)(1). Your food safety plan must include the following:\n1) The written hazard analysis, as required by § 117.130(a)(2);\n2) The written preventive controls, as required by § 117.135(b);\n3) The written supply‐chain program, as required by subpart G;\n4) The written recall plan, as required by § 117.139(a);\n5) The written procedures for monitoring the implementation of the preventive controls, as required by § 117.145(a);\n6) The written corrective action procedures, as required by § 117.150(a)(1); and\n7) The written verification procedures, as required by § 117.165(b).\nYour facility manufactures refrigerated RTE rice noodles in ROP packaging. However, you did not have a food safety plan with any of the required elements for these products. For example, you did not conduct a hazard analysis to identify and evaluate known or reasonably foreseeable hazards for RTE rice noodles manufactured and packaged at your facility to determine whether there are any hazards requiring a preventive control, as required by 21 CFR 117.130(a). Also, you did not identify and implement preventive controls to provide assurances that any hazards requiring a preventive control will be significantly minimized or prevented and the food manufactured, processed, packed, or held by your facility will not be adulterated under section 402 of the Act [see 21 CFR 117.135(a)(1)]. Preventive controls include, as appropriate to the facility and the food, process controls, food allergen controls, sanitation controls, supply-chain controls, and a recall plan [see 21 CFR 117.135(c)]. Preventive controls are subject to preventive control management components (monitoring, verification, and corrective actions) as appropriate to ensure the effectiveness of the preventive controls, taking into account the nature of the preventive control and its role in the facility's food safety system (see 21 CFR 117.140).\nFor example, you did not identify growth and survival of bacterial pathogens, such as B. cereus, L. monocytogenes, and C. botulinum as known or reasonably foreseeable hazards to determine whether they are hazards requiring a preventive control. Your in-process and finished ROP rice noodles are produced without time-temperature and\u002For (b)(4) and are likely to support the growth of bacterial pathogens and\u002For toxin formation. A knowledgeable person manufacturing\u002Fprocessing food in your circumstances would identify growth of bacterial pathogens as a hazard requiring a preventive control (e.g., process controls). Process controls include procedures, practices, and processes to ensure the control of parameters during operations. Where appropriate, process controls must also include the parameters associated with the control of the hazard and the minimum and\u002For maximum values needed to significantly minimize or prevent the hazards requiring a process control [see 21 CFR 117.135(c)(1)].\nDuring the inspection, FDA investigators observed the following instances of time-temperature abuse of the RTE rice noodles:\nOn February 11, 2026, our investigators measured the temperature of cooked in-process RTE Banh Pho Tuoi rice noodle sheets, Lot (b)(4), during the (b)(4) process on Lines (b)(4) and (b)(4) at 9:00 AM at 69°F and 66.5°F, respectively. The rice noodle sheets were stacked (b)(4) sheets in stacks approximately four feet high with a (b)(4) of each stack. At 10:14 AM the temperature of the rice noodle sheets was measured at 71.5°F and 64.5°F; at 12:19 PM the temperature was measured at 69°F and 65°F; and at 3:20 PM, was measured at 69°F and 66°F.\nThe cut noodles are packed in 10 lb. bags with the (b)(4) removed and (b)(4) closed creating the potential for ROP conditions within the bag due to the permeability of the packaging material. The bags are packed in cases, the cases are palletized and wrapped in plastic wrap, and the pallets are transferred from the S Parco facility to the refrigerator at the E Cedar facility before being fully cooled. As noted in the E Cedar facility observations above, Lot 04-23-B1 of Banh Pho Tuoi noodles cooled by only 4.5°F over 26 hours (from 66.5°F to 62°F).\nFurther, FDA sample (#1317731) of refrigerated FRESH RICE STICK NOODLE BANH PHO TUOI (10 lbs., Lot (b)(4)) was collected and analyzed for pH and water activity. The finished product was found to have a pH range of 4.67 to 4.93 (original analysis) and 4.52 to 4.64 (check analysis). The water activity was found to be 1.0 (original analysis) and 0.99 (check analysis). These pH and water activity values may allow for bacterial pathogen growth and toxin formation.\nAdditionally, you did not identify recontamination with environmental pathogens, such as L. monocytogenes, as a known or reasonably foreseeable hazard to determine whether it is a hazard requiring a preventive control. Your RTE rice noodles are exposed to the environment after being (b)(4) and (b)(4) dried and then (b)(4) by employees prior to packaging. The packaged noodles do not receive a lethal treatment or otherwise include another control that would significantly minimize the hazard of recontamination with environmental pathogens.\nContamination with environmental pathogens is a known or reasonably foreseeable hazard. A knowledgeable person manufacturing\u002Fprocessing food in your circumstances would identify contamination with environmental pathogens as a hazard requiring a preventive control (e.g., sanitation controls). Sanitation controls include procedures, practices, and processes to ensure that the facility is maintained in a sanitary condition adequate to significantly minimize or prevent hazards such as environmental pathogens and biological hazards due to employee handling [see 21 CFR 117.135(c)(3)]. In addition, we note that verification activities must include, as appropriate, environmental monitoring if contamination of an RTE food with an environmental pathogen is a hazard requiring a preventive control [see 21 CFR 117.165(a)(3)].\nYour firm’s FDA-483 response dated March 17, 2026 provided a hazard analysis and preventive controls and an environmental monitoring program. We acknowledge that you intend to use pH, (b)(4), and temperature controls to ensure the safety of your finished RTE rice noodle products. However, your process preventive controls for the manufacturing of RTE rice noodles at your S Parco Avenue facility appear to be the same as those provided for your E Cedar Street facility. Accordingly, FDA has the same concerns regarding inadequate controls for bacterial pathogen growth and\u002For toxin formation as those discussed above for the E Cedar Street facility. We also note that the food safety plan, dated March 9, 2026 included in your FDA-483 response did not include a written recall plan as required.\nCurrent Good Manufacturing Practice (21 CFR Part 117, Subpart B):\nE Cedar Street Facility\n1. Your plant was not constructed in such a manner that drip or condensate from fixtures, ducts and pipes does not contaminate food and food-contact surfaces, as required by 21 CFR 117.20(b)(4). Specifically, on January 27, 2026, during the manufacturing of RTE rice noodle sheets (Lot (b)(4)), continuous (b)(4) around the (b)(4) vent hoods on (b)(4) Lines (b)(4) and (b)(4) were observed, with condensate collecting on the edge of the (b)(4) exhaust hoods directly over exposed noodle sheets. Condensate was observed to drip from the hood surface which is located at the (b)(4). The exterior surface of the (b)(4) hood on Line (b)(4) was observed with rust-like discoloration on the outer hood surface where condensate was forming.\nYour response to the FDA-483 indicated that the (b)(4) vent hood was thoroughly cleaned and sanitized to prevent condensation and to remove rust. Your response is not adequate because it does not address how you would prevent condensate from forming and serving as a potential contaminant to food-contact surfaces and to your RTE rice noodle products (b)(4) the (b)(4) in the future.\nS Parco Avenue Facility\n2. You did not clean and sanitize your utensils and equipment in a manner that protects against contamination of food-contact surfaces, as required by 21 CFR 117.35(a). During cleaning and sanitation operations on January 29, 2026 in your S Parco facility, FDA investigators observed employees cleaning soiled equipment in a manner that caused overspray to contact food-contact surfaces of equipment that had already been cleaned.\nYour response to the FDA-483 indicated that personnel were trained to avoid recontamination of cleaned equipment by avoiding splashing water. We will evaluate the adequacy of your corrective action during the next inspection of your facility.\n3. You did not take effective measures to exclude pests from the manufacturing, processing, packing, and holding areas of your facility to protect against contamination of food, as required by 21 CFR 117.35(c). Specifically,\na. On January 27, 2026, during the manufacturing of RTE Banh Pho Tuoi rice noodles (Lot (b)(4)), at least five apparent dead black winged insects were observed in (b)(4) and one bee-like insect was observed on the dispensing table adjacent to the (b)(4) bulk tote. Two live black winged insects were observed on a (b)(4) bag holding rice.\nb. On February 5, 2026, during the manufacturing of RTE Banh Pho Tuoi rice noodles (Lot (b)(4)), two dead apparent cockroaches were observed in the facility. One insect was observed in the drain between the rice noodle (b)(4) lines, and one was observed between pallets of raw rice.\nYour response to the FDA-483 addressed actions taken by your pest control company to treat for cockroaches and actions you have taken to prevent their entry into the facility. An employee training record covering the requirement for personnel to report pest sightings in the production facility was also provided and focused on cockroaches and mouse\u002Frat activity. We note that the (b)(4) rice observed in contact with dead black winged insects was voluntarily discarded on January 27, 2026, following identification of this condition. We will evaluate the adequacy of your corrective actions during the next inspection.\nThis letter is not intended to be an all-inclusive statement of violations that may exist at your facility or in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including applicable FDA regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\nWe also offer the following comments:\nOn February 3, 2026, FDA collected environmental swabs (FDA sample #1309377) from your E Cedar Street facility. Two (2) swabs collected from a (b)(4) tested positive for Listeria grayi. This (b)(4) was approximately (b)(4) area and approximately (b)(4).\nOn February 10, 2026, FDA collected environmental swabs (FDA sample #1322596) from your S Parco Avenue facility. Two (2) swabs tested positive for Listeria innocua (including the food contact surface of the (b)(4) above the (b)(4) and the (b)(4) and two (2) locations were positive for Listeria grayi (b)(4) on the (b)(4).\nThese findings can be an indicator of inadequate sanitation and of conditions that support the growth of Listeria monocytogenes (a human pathogen) in your manufacturing facilities.\nWe acknowledge the presence of cooking instructions on your product labeling and your work in establishing the adequacy of these instructions, however your rice noodles are a RTE food as it is reasonably foreseeable that your fully cooked rice noodles will be eaten without further processing that would significantly minimize biological hazards based on how consumers use your product.\nPlease notify FDA in writing, within fifteen (15) working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within fifteen (15) working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\nPlease send your reply to: HFP-OCE-ConventionalFoods@fda.hhs.gov, copying Valerie Potopsingh, Compliance Officer at valerie.potopsingh@fda.hhs.gov or by hardcopy to Food and Drug Administration, Attention: Valerie Potopsingh, Compliance Officer, Human Foods Program – Office of Compliance and Enforcement, Office of Enforcement – Division of Conventional Foods Enforcement (HFS-607), 5001 Campus Drive, College Park, MD 20740. If you have any questions regarding this letter, you may contact Valerie Potopsingh, Compliance Officer, via email at valerie.potopsingh@fda.hhs.gov. Please include reference CMS #730689 on any submissions and within the subject line of any email correspondence to the agency.\nSincerely,\n\u002FS\u002F\nMaria S. Knirk, JD MBA\nDirector\nOffice of Enforcement\nOffice of Compliance and Enforcement\nHuman Foods Program","Rama Food Manufacture Corp.","rama-food-manufacture-corp-730689-09222026","2026-11-03T01:02:17.615107+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Frama-food-manufacture-corp-730689-09222026","2026-11-17T01:02:03.701861+00:00","2026-10-27","730689","Food & Beverages","Ms. Karen Ving, President","2026-11-03T01:03:03.566+00:00","VIA ELECTRONIC DELIVERY","2026-09-22",{"id":56,"raw":57,"subject":12,"body_html":62,"body_text":63,"firm_name":64,"letter_id":65,"created_at":66,"fei_number":19,"letter_url":67,"updated_at":68,"action_type":22,"case_status":23,"posted_date":69,"marcs_cms_no":70,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":71,"body_fetched_at":72,"delivery_method":73,"recipient_title":19,"reference_number":74,"action_taken_date":75,"medical_device_id":19,"response_letter_date":19},928,[58,59,60,11,61,13,13,13],"\u003Ctime datetime=\"2025-04-29T04:00:00Z\">04\u002F29\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-04-09T04:00:00Z\">04\u002F09\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fdyno-manufacturing-inc-700785-04092025\">Dyno Manufacturing, Inc.\u003C\u002Fa>","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated\u003Cbr \u002F>\r\n","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-25-63\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Ms. Jennifer A. Boofer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>General Manager\u002FQA Manager \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Dyno Manufacturing, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2 Fox Industrial Dr.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Madison\u003C\u002Fspan>, \u003Cspan>IL\u003C\u002Fspan> \u003Cspan>62060-1155\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter \u003C\u002Fstrong>320-25-63\u003C\u002Fp>\u003Cp>April 9, 2025\u003Cbr>\u003Cbr>Dear Ms. Boofer:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Dyno Manufacturing, Inc., FEI 3017219182, at 2 Fox Industrial Dr., Madison, IL 62060-1155, from October 28 to November 1, 2024.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>We reviewed your November 21, 2024 response to our Form FDA 483 in detail.\u003C\u002Fp>\u003Cp>During our inspection, our investigator observed specific violations including, but not limited to, the following.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to conduct at least one test to verify the identity of each component of a drug product. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm manufactures over-the-counter (OTC) hand sanitizer and antibacterial hand soap drug products without adequate assurance of the quality of raw materials. For example, you did not adequately test incoming raw materials, including identity testing of each shipment of each component lot (e.g., ethanol, glycerin, propylene glycol) used in the manufacture of your OTC drug products. You stated that you were aware of the legal requirement for testing components, but accepted the at-risk components based on their suppliers’ certificate of analysis (COA).\u003C\u002Fp>\u003Cp>\u003Cem>Glycerin\u003C\u002Fem>\u003C\u002Fp>\u003Cp>You failed to adequately test your incoming components at high risk of diethylene glycol (DEG) or ethylene glycol (EG) contamination for identity before using them to manufacture your drug products. This includes, but is not limited to, testing of glycerin you used in manufacturing your drug products to determine its appropriate identity.\u003C\u002Fp>\u003Cp>Identity testing for glycerin and certain other high-risk drug components include a limit test in the United States Pharmacopeia (USP) to ensure that the component meets the relevant safety limits for levels of DEG or EG. Because you did not perform identity testing on each shipment of each lot using the USP identification test that detects these hazardous impurities, you failed to assure the acceptability of these components for use in the manufacture of your drug products.\u003C\u002Fp>\u003Cp>The use of ingredients contaminated with DEG or EG has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document \u003Cem>Testing of Glycerin, Propylene Glycol, Maltitol Solution, Hydrogenated Starch Hydrolysate, Sorbitol Solution, and Other High-Risk Drug Components for Diethylene Glycol and Ethylene Glycol\u003C\u002Fem> to help you meet the CGMP requirements when manufacturing drugs containing ingredients at high-risk for DEG or EG contamination at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F167974\u002Fdownload.\u003C\u002Fp>\u003Cp>\u003Cem>Ethanol\u003C\u002Fem>\u003C\u002Fp>\u003Cp>You failed to adequately test your incoming ethanol, used as an active ingredient, for methanol. During the inspection, you indicated that your supplier tests ethanol for methanol prior to shipment. You relied on your suppliers’ COA, and you have not established the reliability of your component suppliers’ test analyses at appropriate intervals. In addition, the supplier’s COA for ethanol did not include test results for methanol.\u003C\u002Fp>\u003Cp>Without adequate testing you do not have scientific evidence that your raw materials conform to appropriate specifications prior to use in the manufacture of your drug products. As a manufacturer, you have a responsibility to sample, test, and examine drug components before use in production to assure adequate quality.\u003C\u002Fp>\u003Cp>The use of ethanol contaminated with methanol has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document Policy for Testing of Alcohol (Ethanol) and Isopropyl Alcohol for Methanol at: https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F173005\u002Fdownload.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic revalidation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot. In the case of glycerin, propylene glycol, and certain additional high-risk components we note that this includes the performance of parts A, B, and C of the USP monograph.\u003C\u002Fli>\u003Cli>The chemical quality control specifications you use to test each incoming lot of high-risk drug components to determine acceptability for use in manufacturing.\u003C\u002Fli>\u003Cli>A comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\u003C\u002Fli>\u003Cli>A summary of your program for qualifying and overseeing contract facilities that test the drug products you manufacture.\u003C\u002Fli>\u003Cli>A summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your standard operating procedure (SOP) that describes this COA validation program.\u003C\u002Fli>\u003Cli>A commitment to provide DEG and EG test results, no later than 30 calendar days from the date of this letter, from testing retains for all lots of high-risk drug components used in the manufacture of drug products. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product batches for the presence of DEG and EG.\u003C\u002Fli>\u003Cli>A full risk assessment for drug products that are within expiry which contain any ingredient at risk for DEG or EG contamination (including, but not limited to, glycerin). Take prompt and appropriate actions to determine the safety of all lots of the component(s) and any related drug product that could contain DEG or EG, including customer notifications and product recalls for any contaminated lots. Identify additional appropriate corrective actions and preventive actions (CAPAs) that secure supply chains in the future, including, but not limited to, ensuring that all incoming raw material lots are from fully qualified manufacturers and free from unsafe impurities. Detail these actions in your response to this letter.\u003C\u002Fli>\u003Cli>Methanol testing for all hand sanitizer batches released and distributed in the United States within expiry.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm failed to assure that the drug product bore an expiration date that was supported by appropriate stability testing (21 CFR 211.137(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You failed to establish a stability testing program to support the expiry of your distributed drug products. You did not perform any stability studies for your OTC hand sanitizer and antibacterial hand soap drug products to support their assigned \u003Cstrong>(b)(4)\u003C\u002Fstrong> expiry period. Also, you did not have an approved stability program procedure at the time of inspection.\u003C\u002Fp>\u003Cp>In your response, you commit to drafting stability protocols for all your hand sanitizer and antibacterial soap products and qualifying a contract laboratory to utilize their stability chambers for your stability studies. Your interim remediation is to test “representative retain samples” of your marketed products for assay to show stability under ambient conditions.\u003C\u002Fp>\u003Cp>Your response is inadequate. Your interim remediation of testing your “retain samples” for assay does not address other critical quality attributes for drug stability, including microbiological and impurity testing.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>Your plan for continuing stability studies for your drug products through expiry, including detailed timelines. This plan should also include an assessment of the stability of drug product currently on the U.S. market.\u003C\u002Fli>\u003Cli>Your stability data to demonstrate that the chemical, purity, and microbiological properties of your drug products will remain within specification throughout their expiry period.\u003C\u002Fli>\u003Cli>Your action plan to address any product quality or patient safety risks for your drug products in U.S. distribution, including potential customer notifications and recalls.\u003C\u002Fli>\u003Cli>A comprehensive, independent assessment and CAPA plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\u003Cbr>o Stability indicating methods.\u003Cbr>o Stability studies for each drug product in its marketed container-closure system before distribution is permitted.\u003Cbr>o An ongoing program in which representative batches of each product are added each year to the program to determine if the shelf-life claim remains valid detailed definition of the specific attributes to be tested at each station (timepoint).\u003Cbr>o All procedures that describe these and other activities of your remediated stability program.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>3. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You failed to validate your production and process controls. You did not have assurance that you are capable of consistently manufacturing your drug product with defined quality attributes. Your firm lacked a process validation program and data to support fundamental process parameters such as mixing speed, time, and temperature.\u003C\u002Fp>\u003Cp>From October 2022 to 2024, you manufactured approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> batches of liquid OTC hand sanitizer and antibacterial hand soap drug products using unvalidated processes.\u003C\u002Fp>\u003Cp>Additionally, you did not perform equipment qualification studies, and the inspection documented that cleaning validation studies have not been completed for your drug product manufacturing equipment. You have not established evidence to show your equipment functions and operates as expected or that your cleaning processes for this equipment prevents product contamination.\u003C\u002Fp>\u003Cp>In your response, you commit to completing process validation studies and equipment qualification activities, however, your response is inadequate because you do not provide product impact assessments for ongoing manufacturing and distributed drug products.\u003C\u002Fp>\u003Cp>Process validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies include intensive monitoring and testing throughout each significant process stage to characterize intra-batch variation and evaluate batches to determine whether an initial state of control has been established.\u003C\u002Fp>\u003Cp>Successful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle.\u003C\u002Fp>\u003Cp>See the FDA's guidance for industry, \u003Cem>Process Validation: General Principles and Practices\u003C\u002Fem> for general principles and approaches that the FDA considers appropriate elements of process validation at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process performance qualification (PPQ), and ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control.\u003C\u002Fli>\u003Cli>A timeline for performing PPQ for each of your marketed drug products. Also include an explanation how you will ensure proper satisfactory PPQ studies are performed prior to future distribution of any drug products.\u003C\u002Fli>\u003Cli>A risk assessment for the distributed drug product(s) produced without performing any process validation studies.\u003C\u002Fli>\u003Cli>Process performance protocol(s), and written procedures for qualification of equipment and facilities.\u003C\u002Fli>\u003Cli>A detailed program for designing, validating, maintaining, controlling and monitoring each of your manufacturing processes that includes vigilant monitoring of intra-batch and inter-batch variation to ensure an ongoing state of control. Also, include your program for qualification of your equipment and facility.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>4. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your quality unit (QU) did not adequately exercise its authority and responsibilities including, but not limited to, implementing effective procedures and conducting adequate oversight. For example, you failed to ensure the following:\u003C\u002Fp>\u003Cul>\u003Cli>Establishment of written records describing the evaluation of quality standards of each drug product at least annually to determine the need for changes in drug product specifications, manufacturing, or control procedures (21 CFR 211.180(e)).\u003C\u002Fli>\u003Cli>Establishment of adequate written procedures defining QU responsibilities and controls (21 CFR 211.22(d)).\u003C\u002Fli>\u003Cli>Appropriate controls over computer or related systems to assure that only authorized personnel institute changes in master production and control records, or other records as required by 21 CFR 211.68(b).\u003C\u002Fli>\u003C\u002Ful>\u003Cp>In your response, you initiated a CAPA to complete annual product reviews for all your liquid OTC hand sanitizers and antibacterial hand soaps manufactured. You also state under your effectiveness criteria, you will review and address data trends and implement CAPAs as appropriate based on your findings.\u003C\u002Fp>\u003Cp>Your response is inadequate. You do not provide information on how you will ensure annual product reviews will be completed routinely for all your drug products.\u003C\u002Fp>\u003Cp>Your firm’s quality systems are inadequate. See FDA’s guidance document \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem> for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A complete assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\u003C\u002Fli>\u003Cli>A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003Cbr>o A determination of whether procedures used by your firm are robust and appropriate.\u003Cbr>o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\u003Cbr>o A complete and final review of each batch and its related information before the QU disposition decision.\u003Cbr>o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3017219182 and ATTN: Sai Dharmaraj.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>&nbsp;\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nReference #:\n\n320-25-63\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMs. Jennifer A. Boofer\n\nRecipient Title\n\nGeneral Manager\u002FQA Manager\n\nDyno Manufacturing, Inc.\n\n2 Fox Industrial Dr.\n\nMadison, IL 62060-1155\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-25-63\nApril 9, 2025\n\nDear Ms. Boofer:\nThe United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Dyno Manufacturing, Inc., FEI 3017219182, at 2 Fox Industrial Dr., Madison, IL 62060-1155, from October 28 to November 1, 2024.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nWe reviewed your November 21, 2024 response to our Form FDA 483 in detail.\nDuring our inspection, our investigator observed specific violations including, but not limited to, the following.\n1. Your firm failed to conduct at least one test to verify the identity of each component of a drug product. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\nYour firm manufactures over-the-counter (OTC) hand sanitizer and antibacterial hand soap drug products without adequate assurance of the quality of raw materials. For example, you did not adequately test incoming raw materials, including identity testing of each shipment of each component lot (e.g., ethanol, glycerin, propylene glycol) used in the manufacture of your OTC drug products. You stated that you were aware of the legal requirement for testing components, but accepted the at-risk components based on their suppliers’ certificate of analysis (COA).\nGlycerin\nYou failed to adequately test your incoming components at high risk of diethylene glycol (DEG) or ethylene glycol (EG) contamination for identity before using them to manufacture your drug products. This includes, but is not limited to, testing of glycerin you used in manufacturing your drug products to determine its appropriate identity.\nIdentity testing for glycerin and certain other high-risk drug components include a limit test in the United States Pharmacopeia (USP) to ensure that the component meets the relevant safety limits for levels of DEG or EG. Because you did not perform identity testing on each shipment of each lot using the USP identification test that detects these hazardous impurities, you failed to assure the acceptability of these components for use in the manufacture of your drug products.\nThe use of ingredients contaminated with DEG or EG has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document Testing of Glycerin, Propylene Glycol, Maltitol Solution, Hydrogenated Starch Hydrolysate, Sorbitol Solution, and Other High-Risk Drug Components for Diethylene Glycol and Ethylene Glycol to help you meet the CGMP requirements when manufacturing drugs containing ingredients at high-risk for DEG or EG contamination at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F167974\u002Fdownload.\nEthanol\nYou failed to adequately test your incoming ethanol, used as an active ingredient, for methanol. During the inspection, you indicated that your supplier tests ethanol for methanol prior to shipment. You relied on your suppliers’ COA, and you have not established the reliability of your component suppliers’ test analyses at appropriate intervals. In addition, the supplier’s COA for ethanol did not include test results for methanol.\nWithout adequate testing you do not have scientific evidence that your raw materials conform to appropriate specifications prior to use in the manufacture of your drug products. As a manufacturer, you have a responsibility to sample, test, and examine drug components before use in production to assure adequate quality.\nThe use of ethanol contaminated with methanol has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document Policy for Testing of Alcohol (Ethanol) and Isopropyl Alcohol for Methanol at: https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F173005\u002Fdownload.\nIn response to this letter, provide:\nA description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic revalidation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot. In the case of glycerin, propylene glycol, and certain additional high-risk components we note that this includes the performance of parts A, B, and C of the USP monograph.\nThe chemical quality control specifications you use to test each incoming lot of high-risk drug components to determine acceptability for use in manufacturing.\nA comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\nA summary of your program for qualifying and overseeing contract facilities that test the drug products you manufacture.\nA summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your standard operating procedure (SOP) that describes this COA validation program.\nA commitment to provide DEG and EG test results, no later than 30 calendar days from the date of this letter, from testing retains for all lots of high-risk drug components used in the manufacture of drug products. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product batches for the presence of DEG and EG.\nA full risk assessment for drug products that are within expiry which contain any ingredient at risk for DEG or EG contamination (including, but not limited to, glycerin). Take prompt and appropriate actions to determine the safety of all lots of the component(s) and any related drug product that could contain DEG or EG, including customer notifications and product recalls for any contaminated lots. Identify additional appropriate corrective actions and preventive actions (CAPAs) that secure supply chains in the future, including, but not limited to, ensuring that all incoming raw material lots are from fully qualified manufacturers and free from unsafe impurities. Detail these actions in your response to this letter.\nMethanol testing for all hand sanitizer batches released and distributed in the United States within expiry.\n2. Your firm failed to assure that the drug product bore an expiration date that was supported by appropriate stability testing (21 CFR 211.137(a)).\nYou failed to establish a stability testing program to support the expiry of your distributed drug products. You did not perform any stability studies for your OTC hand sanitizer and antibacterial hand soap drug products to support their assigned (b)(4) expiry period. Also, you did not have an approved stability program procedure at the time of inspection.\nIn your response, you commit to drafting stability protocols for all your hand sanitizer and antibacterial soap products and qualifying a contract laboratory to utilize their stability chambers for your stability studies. Your interim remediation is to test “representative retain samples” of your marketed products for assay to show stability under ambient conditions.\nYour response is inadequate. Your interim remediation of testing your “retain samples” for assay does not address other critical quality attributes for drug stability, including microbiological and impurity testing.\nIn response to this letter, provide:\nYour plan for continuing stability studies for your drug products through expiry, including detailed timelines. This plan should also include an assessment of the stability of drug product currently on the U.S. market.\nYour stability data to demonstrate that the chemical, purity, and microbiological properties of your drug products will remain within specification throughout their expiry period.\nYour action plan to address any product quality or patient safety risks for your drug products in U.S. distribution, including potential customer notifications and recalls.\nA comprehensive, independent assessment and CAPA plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\no Stability indicating methods.\no Stability studies for each drug product in its marketed container-closure system before distribution is permitted.\no An ongoing program in which representative batches of each product are added each year to the program to determine if the shelf-life claim remains valid detailed definition of the specific attributes to be tested at each station (timepoint).\no All procedures that describe these and other activities of your remediated stability program.\n3. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\nYou failed to validate your production and process controls. You did not have assurance that you are capable of consistently manufacturing your drug product with defined quality attributes. Your firm lacked a process validation program and data to support fundamental process parameters such as mixing speed, time, and temperature.\nFrom October 2022 to 2024, you manufactured approximately (b)(4) batches of liquid OTC hand sanitizer and antibacterial hand soap drug products using unvalidated processes.\nAdditionally, you did not perform equipment qualification studies, and the inspection documented that cleaning validation studies have not been completed for your drug product manufacturing equipment. You have not established evidence to show your equipment functions and operates as expected or that your cleaning processes for this equipment prevents product contamination.\nIn your response, you commit to completing process validation studies and equipment qualification activities, however, your response is inadequate because you do not provide product impact assessments for ongoing manufacturing and distributed drug products.\nProcess validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies include intensive monitoring and testing throughout each significant process stage to characterize intra-batch variation and evaluate batches to determine whether an initial state of control has been established.\nSuccessful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle.\nSee the FDA's guidance for industry, Process Validation: General Principles and Practices for general principles and approaches that the FDA considers appropriate elements of process validation at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\nIn response to this letter, provide:\nA detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process performance qualification (PPQ), and ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control.\nA timeline for performing PPQ for each of your marketed drug products. Also include an explanation how you will ensure proper satisfactory PPQ studies are performed prior to future distribution of any drug products.\nA risk assessment for the distributed drug product(s) produced without performing any process validation studies.\nProcess performance protocol(s), and written procedures for qualification of equipment and facilities.\nA detailed program for designing, validating, maintaining, controlling and monitoring each of your manufacturing processes that includes vigilant monitoring of intra-batch and inter-batch variation to ensure an ongoing state of control. Also, include your program for qualification of your equipment and facility.\n4. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\nYour quality unit (QU) did not adequately exercise its authority and responsibilities including, but not limited to, implementing effective procedures and conducting adequate oversight. For example, you failed to ensure the following:\nEstablishment of written records describing the evaluation of quality standards of each drug product at least annually to determine the need for changes in drug product specifications, manufacturing, or control procedures (21 CFR 211.180(e)).\nEstablishment of adequate written procedures defining QU responsibilities and controls (21 CFR 211.22(d)).\nAppropriate controls over computer or related systems to assure that only authorized personnel institute changes in master production and control records, or other records as required by 21 CFR 211.68(b).\nIn your response, you initiated a CAPA to complete annual product reviews for all your liquid OTC hand sanitizers and antibacterial hand soaps manufactured. You also state under your effectiveness criteria, you will review and address data trends and implement CAPAs as appropriate based on your findings.\nYour response is inadequate. You do not provide information on how you will ensure annual product reviews will be completed routinely for all your drug products.\nYour firm’s quality systems are inadequate. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\nIn response to this letter, provide:\nA complete assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\nA comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\no A determination of whether procedures used by your firm are robust and appropriate.\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\no A complete and final review of each batch and its related information before the QU disposition decision.\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\nCGMP Consultant Recommended\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3017219182 and ATTN: Sai Dharmaraj.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research","Dyno Manufacturing, Inc.","dyno-manufacturing-inc-700785-04092025","2026-08-18T06:42:28.676509+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fdyno-manufacturing-inc-700785-04092025","2026-10-26T08:08:28.949733+00:00","2025-04-29","700785","Ms. Jennifer A. Boofer","2026-08-19T16:50:06.657+00:00","Via Email","320-25-63","2025-04-09",{"id":77,"raw":78,"subject":12,"body_html":82,"body_text":83,"firm_name":84,"letter_id":85,"created_at":86,"fei_number":19,"letter_url":87,"updated_at":88,"action_type":22,"case_status":23,"posted_date":89,"marcs_cms_no":90,"product_type":91,"closeout_date":19,"issuing_office":11,"recipient_name":92,"body_fetched_at":93,"delivery_method":94,"recipient_title":19,"reference_number":95,"action_taken_date":96,"medical_device_id":19,"response_letter_date":19},3693,[79,80,81,11,12,13,13,13],"\u003Ctime datetime=\"2026-06-16T04:00:00Z\">06\u002F16\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-06-05T04:00:00Z\">06\u002F05\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsante-manufacturing-inc-724931-06052026\">Sante Manufacturing Inc.  \u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Electronic Mail - Return Receipt Requested\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-26-94\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n                          \u003Cbr>Over-the-Counter Drugs\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Wayne Kirby\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Sante Manufacturing Inc.  \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>516 John Street N 11A &amp; 11B\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Aylmer\u003C\u002Fspan> \u003Cspan>ON\u003C\u002Fspan> \u003Cspan>N5H 2B8\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Canada\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-26-94\u003C\u002Fp>\u003Cp>June 5, 2026\u003C\u002Fp>\u003Cp>Dear Mr. Kirby:\u003C\u002Fp>\u003Cp>Your facility is registered with the United States Food and Drug Administration (FDA) as a manufacturer of over-the-counter (OTC) drug products. FDA has reviewed the records you submitted in response to our July 7, 2025, request and subsequent correspondence for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) for your facility, Sante Manufacturing Inc., FEI 3021535057, at 516 John Street N 11A &amp; 11B Aylmer, Ontario, Canada.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations, parts 210 and 211 (21 CFR, parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding of drugs as described in your response to our 704(a)(4) request do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. 351(a)(2)(B)).\u003C\u002Fp>\u003Cp>Following review of records and other information provided pursuant to section 704(a)(4) of the FD&amp;C Act, significant violations were observed including, but not limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to conduct at least one test to verify the identity of each component of a drug product. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm manufactures OTC drug products such as \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Based on the records and information you provided, you did not demonstrate that you adequately tested each shipment of each lot of incoming \u003Cstrong>(b)(4)\u003C\u002Fstrong>, a component at high risk for \u003Cstrong>(b)(4)\u003C\u002Fstrong> contamination, prior to its use in manufacturing. This includes testing of \u003Cstrong>(b)(4)\u003C\u002Fstrong> used in manufacturing drug products to determine its appropriate identity. Your firm also relied on the supplier’s certificate of analysis (COA) and accepted the \u003Cstrong>(b)(4)\u003C\u002Fstrong> component based on your supplier’s COA without establishing the reliability of your supplier’s test analyses at appropriate intervals.\u003C\u002Fp>\u003Cp>The use of ingredients contaminated with \u003Cstrong>(b)(4)\u003C\u002Fstrong> has resulted in various lethal poisoning incidents in humans worldwide. See \u003Cstrong>(b)(4)\u003C\u002Fstrong> to help you meet the CGMP requirements when manufacturing drugs containing ingredients at high-risk for \u003Cstrong>(b)(4)\u003C\u002Fstrong> contamination at \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>Without adequate testing and confirmation of reliability of supplier test results, you lack scientific evidence that the components or drug products conform to appropriate specifications prior to use in the drug products you manufacture.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A commitment to provide \u003Cstrong>(b)(4)\u003C\u002Fstrong> test results, no later than 30 calendar days from the date of this letter, from testing retains for all lots of high-risk drug components used in the manufacture of drug products. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product batches for the presence of \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fli>\u003Cli>A full risk assessment for drug products that are within expiry which contain any ingredient at risk for \u003Cstrong>(b)(4)\u003C\u002Fstrong> contamination (including, but not limited to, \u003Cstrong>(b)(4)\u003C\u002Fstrong>). Take prompt and appropriate actions to determine the safety of all lots of the component(s) and any related drug product that could contain \u003Cstrong>(b)(4)\u003C\u002Fstrong>, including customer notifications and product recalls for any contaminated lots. Identify additional appropriate corrective actions and preventive actions (CAPA) that secure supply chains in the future, including, but not limited to, ensuring that all incoming raw material lots are from fully qualified manufacturers and free from unsafe impurities. Detail these actions in your response to this letter.\u003C\u002Fli>\u003Cli>A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic revalidation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot. In the case of \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and certain additional high-risk components we note that this includes the performance of parts \u003Cstrong>(b)(4)\u003C\u002Fstrong> of the United States Pharmacopeia (USP) monograph.\u003C\u002Fli>\u003Cli>The chemical quality control specifications you use to test each incoming lot of high-risk drug components to determine acceptability for use in manufacturing.\u003C\u002Fli>\u003Cli>A comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based on the records and information you provided, you did not demonstrate that you have adequately qualified your \u003Cstrong>(b)(4)\u003C\u002Fstrong> system. Additionally, you did not demonstrate that you adequately monitor your \u003Cstrong>(b)(4)\u003C\u002Fstrong> system. Because you use \u003Cstrong>(b)(4)\u003C\u002Fstrong> from this system as a component in your drug products, you should ensure that it meets, at a minimum, the USP \u003Cstrong>(b)(4) \u003C\u002Fstrong>monograph testing requirements and appropriate microbial limits in light of its intended use. Further, you did not demonstrate that you have an appropriate process validation program.\u003C\u002Fp>\u003Cp>Process validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies include intensive monitoring and testing throughout each significant process stage to characterize intra-batch variation and evaluate batches to determine whether an initial state of control has been established.\u003C\u002Fp>\u003Cp>Successful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle.\u003C\u002Fp>\u003Cp>See FDA’s guidance document Process Validation: General Principles and Practices for general principles and approaches that FDA considers appropriate elements of process validation at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A detailed summary of your validation program for ensuring a state of control throughout the product lifecycle along with associated procedures. Describe your program for process performance qualification (PPQ) and ongoing vigilant monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control. Also, describe your equipment and facility qualification program.\u003C\u002Fli>\u003Cli>A timeline for performing appropriate PPQ for each of your marketed drug products. Also provide a risk assessment and any follow-up actions to be taken for the distributed drug products produced without performing any process validation studies.\u003C\u002Fli>\u003Cli>Process performance protocol(s), and written procedures for qualification of equipment and facilities.\u003C\u002Fli>\u003Cli>A procedure for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> system monitoring that specifies routine microbial testing of \u003Cstrong>(b)(4)\u003C\u002Fstrong> to ensure its acceptability for use in each batch of drug products produced by your firm.\u003C\u002Fli>\u003Cli>The current action\u002Falert limits for total counts and objectionable organisms used for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> system. Ensure that the total count limits for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> are appropriately stringent in view of the intended use of each of the products produced by your firm.\u003C\u002Fli>\u003Cli>A procedure governing your program for ongoing control, maintenance, and monitoring that ensures the system consistently produces \u003Cstrong>(b)(4)\u003C\u002Fstrong> that meets \u003Cstrong>(b)(4)\u003C\u002Fstrong> USP monograph specifications and appropriate microbial limits.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>3. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based on the records and the information you provided, you did not demonstrate that your quality unit (QU) adequately exercises its authority and responsibilities including, but not limited to, implementing effective procedures and conducting adequate oversight of the drug products you manufacture. For example, your QU failed to ensure:\u003C\u002Fp>\u003Cul>\u003Cli>Establishment of an appropriate written testing program designed to assess the stability characteristics of drug products and to use results of stability testing to determine appropriate storage conditions and expiration dates \u003Cstrong>(21 CFR 211.166(a))\u003C\u002Fstrong>.\u003C\u002Fli>\u003Cli>Appropriate validation of your analytical methods \u003Cstrong>(21CFR 211.160(b))\u003C\u002Fstrong>.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Significant findings in this letter demonstrate that your firm does not operate an effective quality system in accord with CGMP. In addition to the lack of effective management oversight of your production operations, we found your QU is not enabled to exercise proper authority and\u002For has insufficiently implemented its responsibilities. Executive management should immediately and comprehensively assess your company’s global manufacturing operations to ensure that your systems, processes, and products conform to FDA requirements.\u003C\u002Fp>\u003Cp>Your firm’s quality systems are inadequate. For guidance on establishing and maintaining CGMP-compliant quality systems, see FDA guidance documents: \u003Cem>Q8(R2) Pharmaceutical Development \u003C\u002Fem>at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71535\u002Fdownload,\u003Cem> Q9(R1) Quality Risk Management\u003C\u002Fem> at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fq9r1-quality-risk-management and \u003Cem>Q10 Pharmaceutical Quality System\u003C\u002Fem> at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71553\u002Fdownload.\u003C\u002Fp>\u003Cp>In response to this letter, provide a comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003C\u002Fp>\u003Cul>\u003Cli>A determination of whether procedures used by your firm are robust and appropriate\u003C\u002Fli>\u003Cli>Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\u003C\u002Fli>\u003Cli>A complete and final review of each batch and its related information before the QU disposition decision\u003C\u002Fli>\u003Cli>Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your CAPAs before you pursue resolution of your firm’s compliance status with FDA.\u003C\u002Fp>\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>FDA placed all drugs and drug products offered for import into the United States from your firm on Import Alert 66-40 on April 27, 2026.\u003C\u002Fp>\u003Cp>Correct any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\u003Cp>Failure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at Sante Manufacturing Inc., at 516 John Street N 11A &amp; 11B, Aylmer, Ontario, Canada, into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3021535057 and ATTN: LaKeesha M. Sifontes.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Electronic Mail - Return Receipt Requested\n\nReference #:\n\n320-26-94\n\nProduct:\n\nDrugs\n\nOver-the-Counter Drugs\n\nRecipient:\n\nRecipient Name\n\nMr. Wayne Kirby\n\nRecipient Title\n\nOwner\n\nSante Manufacturing Inc.\n\n516 John Street N 11A & 11B\n\nAylmer ON N5H 2B8\n\nCanada\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-26-94\nJune 5, 2026\nDear Mr. Kirby:\nYour facility is registered with the United States Food and Drug Administration (FDA) as a manufacturer of over-the-counter (OTC) drug products. FDA has reviewed the records you submitted in response to our July 7, 2025, request and subsequent correspondence for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) for your facility, Sante Manufacturing Inc., FEI 3021535057, at 516 John Street N 11A & 11B Aylmer, Ontario, Canada.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations, parts 210 and 211 (21 CFR, parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding of drugs as described in your response to our 704(a)(4) request do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 351(a)(2)(B)).\nFollowing review of records and other information provided pursuant to section 704(a)(4) of the FD&C Act, significant violations were observed including, but not limited to, the following:\n1. Your firm failed to conduct at least one test to verify the identity of each component of a drug product. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\nYour firm manufactures OTC drug products such as (b)(4). Based on the records and information you provided, you did not demonstrate that you adequately tested each shipment of each lot of incoming (b)(4), a component at high risk for (b)(4) contamination, prior to its use in manufacturing. This includes testing of (b)(4) used in manufacturing drug products to determine its appropriate identity. Your firm also relied on the supplier’s certificate of analysis (COA) and accepted the (b)(4) component based on your supplier’s COA without establishing the reliability of your supplier’s test analyses at appropriate intervals.\nThe use of ingredients contaminated with (b)(4) has resulted in various lethal poisoning incidents in humans worldwide. See (b)(4) to help you meet the CGMP requirements when manufacturing drugs containing ingredients at high-risk for (b)(4) contamination at (b)(4).\nWithout adequate testing and confirmation of reliability of supplier test results, you lack scientific evidence that the components or drug products conform to appropriate specifications prior to use in the drug products you manufacture.\nIn response to this letter, provide:\nA commitment to provide (b)(4) test results, no later than 30 calendar days from the date of this letter, from testing retains for all lots of high-risk drug components used in the manufacture of drug products. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product batches for the presence of (b)(4).\nA full risk assessment for drug products that are within expiry which contain any ingredient at risk for (b)(4) contamination (including, but not limited to, (b)(4)). Take prompt and appropriate actions to determine the safety of all lots of the component(s) and any related drug product that could contain (b)(4), including customer notifications and product recalls for any contaminated lots. Identify additional appropriate corrective actions and preventive actions (CAPA) that secure supply chains in the future, including, but not limited to, ensuring that all incoming raw material lots are from fully qualified manufacturers and free from unsafe impurities. Detail these actions in your response to this letter.\nA description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic revalidation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot. In the case of (b)(4), and certain additional high-risk components we note that this includes the performance of parts (b)(4) of the United States Pharmacopeia (USP) monograph.\nThe chemical quality control specifications you use to test each incoming lot of high-risk drug components to determine acceptability for use in manufacturing.\nA comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\n2. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\nBased on the records and information you provided, you did not demonstrate that you have adequately qualified your (b)(4) system. Additionally, you did not demonstrate that you adequately monitor your (b)(4) system. Because you use (b)(4) from this system as a component in your drug products, you should ensure that it meets, at a minimum, the USP (b)(4) monograph testing requirements and appropriate microbial limits in light of its intended use. Further, you did not demonstrate that you have an appropriate process validation program.\nProcess validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies include intensive monitoring and testing throughout each significant process stage to characterize intra-batch variation and evaluate batches to determine whether an initial state of control has been established.\nSuccessful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle.\nSee FDA’s guidance document Process Validation: General Principles and Practices for general principles and approaches that FDA considers appropriate elements of process validation at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\nIn response to this letter, provide:\nA detailed summary of your validation program for ensuring a state of control throughout the product lifecycle along with associated procedures. Describe your program for process performance qualification (PPQ) and ongoing vigilant monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control. Also, describe your equipment and facility qualification program.\nA timeline for performing appropriate PPQ for each of your marketed drug products. Also provide a risk assessment and any follow-up actions to be taken for the distributed drug products produced without performing any process validation studies.\nProcess performance protocol(s), and written procedures for qualification of equipment and facilities.\nA procedure for your (b)(4) system monitoring that specifies routine microbial testing of (b)(4) to ensure its acceptability for use in each batch of drug products produced by your firm.\nThe current action\u002Falert limits for total counts and objectionable organisms used for your (b)(4) system. Ensure that the total count limits for your (b)(4) are appropriately stringent in view of the intended use of each of the products produced by your firm.\nA procedure governing your program for ongoing control, maintenance, and monitoring that ensures the system consistently produces (b)(4) that meets (b)(4) USP monograph specifications and appropriate microbial limits.\n3. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\nBased on the records and the information you provided, you did not demonstrate that your quality unit (QU) adequately exercises its authority and responsibilities including, but not limited to, implementing effective procedures and conducting adequate oversight of the drug products you manufacture. For example, your QU failed to ensure:\nEstablishment of an appropriate written testing program designed to assess the stability characteristics of drug products and to use results of stability testing to determine appropriate storage conditions and expiration dates (21 CFR 211.166(a)).\nAppropriate validation of your analytical methods (21CFR 211.160(b)).\nSignificant findings in this letter demonstrate that your firm does not operate an effective quality system in accord with CGMP. In addition to the lack of effective management oversight of your production operations, we found your QU is not enabled to exercise proper authority and\u002For has insufficiently implemented its responsibilities. Executive management should immediately and comprehensively assess your company’s global manufacturing operations to ensure that your systems, processes, and products conform to FDA requirements.\nYour firm’s quality systems are inadequate. For guidance on establishing and maintaining CGMP-compliant quality systems, see FDA guidance documents: Q8(R2) Pharmaceutical Development at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71535\u002Fdownload, Q9(R1) Quality Risk Management at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fq9r1-quality-risk-management and Q10 Pharmaceutical Quality System at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71553\u002Fdownload.\nIn response to this letter, provide a comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\nA determination of whether procedures used by your firm are robust and appropriate\nProvisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\nA complete and final review of each batch and its related information before the QU disposition decision\nOversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\nCGMP Consultant Recommended\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your CAPAs before you pursue resolution of your firm’s compliance status with FDA.\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nFDA placed all drugs and drug products offered for import into the United States from your firm on Import Alert 66-40 on April 27, 2026.\nCorrect any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may inspect to verify that you have completed corrective actions to any violations.\nFailure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at Sante Manufacturing Inc., at 516 John Street N 11A & 11B, Aylmer, Ontario, Canada, into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3021535057 and ATTN: LaKeesha M. Sifontes.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research","Sante Manufacturing Inc.","sante-manufacturing-inc-724931-06052026","2026-08-19T04:06:48.349905+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsante-manufacturing-inc-724931-06052026","2026-10-26T08:09:53.900103+00:00","2026-06-16","724931","Drugs Over-the-Counter Drugs","Mr. Wayne Kirby","2026-08-19T04:36:49.687+00:00","Via Electronic Mail - Return Receipt Requested","320-26-94","2026-06-05",4,{"510k":99,"classification":100,"enforcement":101,"event":102,"event_backfill":103,"pma":104,"warning_letter":105},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-18T04:00:44.748+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]